

VERIFICATION OF TRANSLATION

PCT Application No. PCT/JP99/00089

Filed on January 13, 1999

I, Yoshiyuki KAWAGUCHI, a citizen of Japan and the translator of the document attached, whose address is c/o SERA, TOYAMA, MATSUKURA & KAWAGUCHI, Acropolis 21 Building, 6th Floor, 4-10, Higashi Nihonbashi 3-chome, Chuo-Ku, Tokyo, Japan, state that the following is a true translation of the PCT Application No. PCT/JP99/00089 filed on January 13, 1999 to the best of my knowledge and belief.

Signed at Tokyo, Japan

This 17th day of July, 2008



KAWAGUCHI, Yoshiyuki, Ph.D.

Patent Attorney

SERA, TOYAMA, MATSUKURA & KAWAGUCHI

SPECIFICATION

SUBSTANCE WITH ANTITHROMBIC ACTIVITY AND METHOD FOR
DETECTING GLYCOCALICIN

5.

Technical Field

The present invention relates to substance with
antithrombotic activity and method for detecting
10 glyocalicin. More precisely, it relates to a method
for detecting or measuring a substance that inhibits
binding of von Willebrand factor and glycoprotein Ib,
and means directly used for carrying out the method.

15

Background Art

The global number of patients with thromboses such
as myocardial infarction, cerebral infarction and
peripheral artery occlusive disease is very large, and
20 these diseases are very significant diseases to be
diagnosed and treated. Platelets play a fundamental
role for the onset of these thromboses. In general, if
vascular endothelial cells in blood vessel cavities are
impaired by arteriosclerotic lesion or the like,
25 platelets will adhere to the impaired region to cause
activation, and thus there are formed thrombocytic
thrombi, which eventually develop into occlusive lesions.

As one of the methods for detecting activation of platelets, there is a method of measuring glyocalicin concentration in plasma. Glyocalicin is a protein consisting of an enzymatically cleaved extracellular
5 portion of a membrane glycoprotein present on surfaces of platelets, glycoprotein Ib α chain, and has a molecular weight of about 135 kDa. It is known that glyocalicin concentration in plasma is increased by impairment or activation of platelets, and it is
10 currently used as a marker for detecting presence or absence of thrombotic diseases in clinical diagnosis. (J.H. Beer *et al.*, *Blood*, 83, 691-702, 1994; S. Kunishima *et al.*, *Clin. Chem.*, 37, 169-172, 1991).

Many measurement methods of glyocalicin
15 concentration have been reported, and any of these are based on ELISA (enzyme-linked immunosorbent assay) technique, wherein glyocalicin is detected by the sandwiching method utilizing two kinds of monoclonal antibodies directed to glyocalicin (J.H. Beer *et al.*,
20 *supra*; S. Kunishima *et al.*, *supra*). Briefly, first monoclonal antibodies are immobilized on a 96-well plate or the like as a solid phase, blocked with a protein such as bovine serum albumin (BSA), and then added with patient's plasma (or serum) to be measured.
25 Glyocalicin specifically binds to the monoclonal antibodies immobilized on the solid phase. The plate is washed, and added with second monoclonal antibodies

labeled with an enzyme such as alkaline phosphatase and peroxidase or biotin so that the second antibodies should specifically bind to the glyocalicin bound to the first monoclonal antibodies. After washing, the
5 plate is added with a substrate that can be converted into a substance exhibiting specific absorbance in a UV or visible region, fluorescence or luminescence with the enzyme used as the label of the second antibodies to perform an enzymatic reaction. Since the amount of
10 glyocalicin in the patient's plasma and the binding amount of the second antibodies show positive correlation, the concentration of glyocalicin in the patient's plasma can be measured by quantifying the reaction product produced by the enzymatic reaction. A
15 measurement method for glyocalicin by competitive ELISA utilizing one kind of anti-glyocalicin antibodies has also been reported (H. Bessos *et al.*, *Thromb. Res.*, 59, 497-507, 1990). However, the IC_{50} value of the glyocalicin concentration showing competitive
20 inhibition is about 4 $\mu\text{g/ml}$, and this makes the above measurement unusable for the measurement of the glyocalicin concentration in plasma (it is about 2 $\mu\text{g/ml}$ in a healthy subject, J.H. Beer *et al.*, *supra*).

The aforementioned glyocalicin quantification
25 methods based on the sandwich technique are widely used at present. However, when a similar measurement system is desired to be newly prepared, it is necessary to

obtain two kinds of anti-glycocalicin monoclonal antibodies having different recognition sites. Commercially available monoclonal antibodies are generally very expensive, and the preparation of

5 monoclonal antibodies requires much labor such as acquisition of glycocalicin for immunization, acquisition of hybridoma from a spleen of immunized mouse and screening of a monoclonal antibody-producing cell. Further, it is impossible to measure an absolute

10 value of glycocalicin concentration from the amount of the enzymatic reaction in the aforementioned sandwich ELISA method, and in many cases, it is necessary to measure glycocalicin of several kinds of known concentrations to obtain a calibration curve, and then

15 it is necessary to calculate a concentration in a test sample to be measured based on comparison with the calibration curve. Therefore, it is important to establish a method capable of measuring an absolute concentration of glycocalicin in a simple manner without

20 the complicated preparation of monoclonal antibodies, from a viewpoint of wide use in clinical diagnosis.

Further, in an early stage of onset of thrombosis, von Willebrand factor in blood binds to subendothelial tissues (collagen etc.) exposed due to impairment of

25 vascular endothelial cells, and the membrane glycoprotein, glycoprotein Ib, on platelets binds to the von Willebrand factor. Thus, the platelets adhere to

blood vessel walls, and they are activated (J.P. Cean et al., *J. Lab. Clin. Med.*, 87, 586-596, 1976; K.J. Clemetson et al., *Thromb. Haemost.*, 78, 266-270, 1997). Therefore, it is an important target of antithrombotic
5 drugs for treating or preventing thromboses to inhibit the binding of von Willebrand factor and glycoprotein Ib. However, there are few substances that have been proven to exhibit antithrombotic property by inhibiting the binding of the both proteins.

10 It has been reported that a recombinant protein VCL that has a sequence of from the 504th to 728th amino acid residues of von Willebrand factor shows an antithrombotic action by inhibiting the binding of von Willebrand factor and glycoprotein Ib (K. Azzam et al.,
15 *Thromb. Haemost.*, 73, 318-323, 1995). Further, it has also been reported that a monoclonal antibody AJvW-2 directed to human von Willebrand factor exhibits an antithrombotic activity by specifically binding to von Willebrand factor without showing hemorrhagic tendency
20 (S. Kageyama et al., *Br. J. Pharmacol.*, 122, 165-171, 1997; WO 96/17078). Furthermore, the protein AS1051 derived from snake venom specifically binds to the platelet glycoprotein Ib to similarly exhibit an antithrombotic property without showing hemorrhagic
25 tendency (N. Fukuchi et al., WO 95/08573).

Further, aurintricarboxylic acid (ATA), which is a pigmental compound, has been reported to show an

activity for inhibiting the binding of von Willebrand factor and glycoprotein Ib (M.D. Phillips et al., *Blood*, 72, 1989-1903, 1988). However, it is known that its binding specificity is not high (K. Azzam et al., *Thromb. Haemost.*, 75, 203-210, 1996; D. Mitra et al., *Immunology*, 87, 581-585, 1996; R.M. Lozano et al., *Eur. J. Biochem.*, 248, 30-36, 1997), and that the inhibition activity is exhibited by a polymerized macromolecule fraction (M. Weinstein et al., *Blood*, 78, 2291-2298, 1991; Z. Gua et al., *Thromb. Res.*, 71, 77-88, 1993; H. Matsuno et al., *Circulation*, 96, 1299-1304, 1997) etc.

As described above, although it is an important target of antithrombotic drugs to inhibit the binding of von Willebrand factor and glycoprotein Ib, there is no low molecular weight compound that has reported to inhibit the binding of the both and have an antithrombotic activity, and therefore it is important to find out such a substance for attempting treatment and prevention of thromboses.

As a non-proteinaceous substance that inhibits the binding of von Willebrand factor and glycoprotein Ib, aurintricarboxylic acid (ATA) can be mentioned. However, it is known that it exhibits the inhibitory activity as a polymerized macromolecular substance as already described above. M. Weinstein et al. (*Blood*, 78, 2291-2298, 1991) investigated an activity of ATA fractionated by gel filtration for inhibiting the ristocetin-induced

aggregation, which is von Willebrand factor and glycoprotein Ib dependent platelet aggregation, and concluded that a polymer having a molecular weight of 2500 had the strongest activity. They also showed that
5 fractions eluted as low molecular weight fractions in the gel filtration scarcely have the activity (Figs. 1 and 3 in the aforementioned reference). Moreover, in this report, neither a specific structure nor molecular weight of the ATA polymer showing the activity was
10 specified. It is considered that there are no ATA derivatives exhibiting the inhibitory activity for the binding of von Willebrand factor and glycoprotein Ib among those of which structure can be specified, in view of the facts that, although the synthesis of the ATA
15 monomer has already been reported by R.D. Haugwitz (WO 91/06589), no data were reported so far for demonstrating the inhibition of the binding of von Willebrand factor and glycoprotein Ib as for the monomer or a polymer of which structure can be specified, and
20 evaluation of the activity has been reported by using a gel filtration fraction of ATA polymer even in a recent study (T. Kawasaki et al., *Amer. J. Hematol.*, 47, 6-15, 1994).

In the aforementioned report by M. Weinstein et al.
25 (*Blood*, 78, 2291-2298, 1991), it is described that presence of many negative electric charges (polyanion) and presence of many aromatic rings (polyaromatic) are

necessary for the inhibition of the binding of von Willebrand factor and glycoprotein Ib. The fact that the abundance of negative electric charges is likely to inhibit the binding of von Willebrand factor and glycoprotein Ib is also consistent with the fact that heparin, which is a polysaccharide having negative electric charges, inhibits the binding of von Willebrand factor and glycoprotein Ib (M. Solbel et al., *J. Clin. Invest.*, 87, 1787-1793, 1991). In this report, it is also reported that the activity for inhibiting the binding of von Willebrand factor and glycoprotein Ib is reduced, as the molecular weight of heparin becomes smaller.

Heparin is originally a substance inhibiting thrombin, which is a blood aggregation factor, and the blood aggregation factor X (factor Xa). Although a heparin derivative that was imparted with higher selectivity for the binding of von Willebrand factor and glycoprotein Ib has also been reported (M. Sobel et al., *Circulation*, 93, 992-999, 1996), the average molecular weight of that substance is 10,000 or more.

Among substances that are likely to bind to proteins, there is also reported a substance that shows the selective inhibitory activity to some extent for the binding of von Willebrand factor and glycoprotein Ib. It was demonstrated that Evans Blue, which is a pigmental compound, selectively inhibited the platelet

aggregation in which von Willebrand factor (factor VIII in this reference) was involved (E.P. Kirby et al., *Thrombos. Diathes. Haemorrh.*, 34, 770-779, 1975). However, the experimental results contained in this
5 reference all concerned platelet aggregation under a condition not containing blood plasma, and no reference was made for the activity under a condition where plasma proteins are present. Evans Blue is originally a substance that very firmly binds to serum albumin, and
10 such a property provides its use as means for measurement of blood volume, blood leak from blood vessels in living bodies and so forth (M. Gregersen & R.A. Rawson, *Physiol. Reviews*, 39, 307, 1959). That is, when treatment of living bodies, for example, humans, is
15 intended, such substances that strongly bind to proteins in plasma as mentioned above would not show the effect at all. As such substances, there are sulfobacin (T. Kamiyama et al., *J. Antibiot.*, 48, 924-928, 1995) and so forth. Although sulfobacin showed the specificity for
20 the binding of von Willebrand factor and glycoprotein Ib to some extent according to the above reference, it must not show the activity due to the binding to plasma proteins in blood or blood plasma in view of its detergent-like structure. In fact, its inhibitory
25 activity for the platelet aggregation in plasma was not shown in the aforementioned reference.

As described above, any low molecular compounds

have not been known so far, which can inhibit the binding of von Willebrand factor and glycoprotein Ib in living bodies. Assuming drugs against thrombotic diseases for inhibiting the binding of von Willebrand factor and glycoprotein Ib, if they are used as an injection, they may be a macromolecular compound such as proteins or polymers. However, in order to create a drug of the same mechanism of action that can be orally administered, it is important to find a low molecular weight substance that is not a polymer and completely and selectively inhibits von Willebrand factor and glycoprotein Ib dependent platelet aggregation in blood (in plasma).

However, such compounds have not been found so far. As a reason for this, there can be mentioned the fact that any assay system enabling screening of such a substance in a simple manner has not existed.

As will be described later, in conventionally used assay methods for detecting the binding of von Willebrand factor and glycoprotein Ib, ¹²⁵I-labeled von Willebrand factor are bound to platelets or formalin-fixed platelets. However, such methods suffer from complexity of using the radioactive isotope, and difficulty of obtaining a large amount of sample, i.e., difficulty that blood must be collected from an animal, and platelets must be obtained from it. The methods generally used so far and means for solving the problems

thereof will be specifically described below.

The binding of von Willebrand factor and glycoprotein Ib is not observed under a usual condition, and it is considered that it occurs only under a
5 condition where shear stress is induced in a blood flow (T.T. Vincent et al., *Blood*, 65, 823-831, 1985).
However, as a method for artificially making it possible to observe the binding of the both proteins, there are known addition of an antibiotic, ristocetin (M.A. Howard
10 and B.G. Firkin, *Thromb. Haemost.*, 26, 362-369, 1971), and addition of a protein derived from snake venom, botrocetin (M.S. Read et al., *Proc. Natl. Acad. Sci. USA.*, 75, 4514-4518, 1978). That is, the both substances are known as a substance that binds to a
15 specific site of von Willebrand factor to cause a structural change of the von Willebrand factor, thereby causing the binding of the von Willebrand factor and glycoprotein Ib, which does not occur under a usual condition. As a method for observing the binding of the
20 both proteins, there is the following method reported by Fujimura et al. (Y. Fujimura et al., *Blood*, 77, 113-120, 1991).

That is, human von Willebrand factor is labeled with ^{125}I in a conventional manner, and allowed to bind
25 to formalin-fixed platelets in the presence of a certain amount of ristocetin or botrocetin. This binding occurs due to the specific binding of the von Willebrand factor

to glycoprotein Ib on the surfaces of the immobilized platelets, and after unbound von Willebrand factor are removed by washing, the amount of the both proteins bound to each other can be measured by measuring the amount of ^{125}I . Miura et al. detected the binding of the both proteins by a similar method, wherein platelets were immobilized on a 96-well plate via immobilized anti-platelet membrane protein antibodies instead of the use of formalin-fixed platelets (S. Miura et al., *Anal. Biochem.*, 236, 215-220, 1996). Further, Matsui et al. reported a method of binding glyocalicin, which is a partial protein of the extracellular portion of glycoprotein Iba chain in the presence of botrocetin, to von Willebrand factor bound to collagen immobilized as a solid phase (T. Matsui et al., *J. Biochem.*, 121, 376-381, 1997). Furthermore, Moriki et al. produced a recombinant protein expressing cell that expressed glycoprotein Ib on the membrane, and reported that ^{125}I -labeled von Willebrand factor bound to the glycoprotein Ib on the membrane in the presence of botrocetin. Moriki et al. further produced a cell expressing glycoprotein Ib having a mutation in the amino acid sequence, which bound to von Willebrand factor without any inducing agent, and performed a binding experiment. However, the binding amount was very small compared with the binding amount in the presence of botrocetin or ristocetin (T. Moriki et al., *Blood*, 90, 698-705, 1997).

As described above, all of the methods reported so far for detecting the binding of von Willebrand factor and glycoprotein Ib with high sensitivity are methods by obtaining a large amount of platelets or glycoprotein Ib
5 expressing cells and detecting the binding of von Willebrand factor to them. However, it is extremely laborious to routinely prepare a large amount of platelets or such cells, and therefore it is necessary to develop a method for detecting the binding of von
10 Willebrand factor and glycoprotein Ib in a simpler manner.

Further, all of the conventionally used methods are exclusively methods utilizing addition of a binding inducing substance such as botrocetin or ristocetin to
15 a liquid phase. However, the amount of botrocetin or ristocetin changes the amount of the binding of von Willebrand factor and glycoprotein Ib. Moreover, if a large number of binding experiments are performed by using a 96-well plate, for example, these methods
20 utilizing addition of the inducing substance to the liquid phase are laborious. Furthermore, when the aforementioned low molecular weight substance inhibiting the binding of von Willebrand factor and glycoprotein Ib is searched, an extremely large number of binding
25 experiments must be performed, and therefore it is also important from this viewpoint to solve the aforementioned problem.

As already stated, a true inhibition substance with low molecular weight for the binding of von Willebrand factor and glycoprotein Ib has not been discovered yet. The term "true inhibition substance" used herein means a substance specifically inhibiting the binding of von Willebrand factor and glycoprotein Ib, but does not mean a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib in a non-specific manner, even though it may inhibit the binding of von Willebrand factor and glycoprotein Ib, like substances that generally change structures of proteins such as protein denaturing substances and detergents or substances that non-specifically bind to proteins.

As described above, such true inhibition substances for the binding of von Willebrand factor and glycoprotein Ib have been found among antibodies, proteins derived from snake venom, pigmental substances such as aurintricarboxylic acid (ATA), of which active body is a substance having a high molecular weight. However, no such substance has been known among low molecular weight substances, for example, those having a molecular weight of 2000 or less, in particular, those having a molecular weight of 1000 or less, which are useful for oral administration. Therefore, it has been desired to develop an evaluation system capable of quickly screening such substances.

Disclosure of the Invention

The problems of the aforementioned technical background are summarized in the following three points.

5 (1) Although methods for quantification of glyocalicin is important for diagnosis of thromboses, conventional highly sensitive methods are sandwich ELISA methods. Therefore, two kinds of monoclonal antibodies having different recognition sites are required, and a
10 calibration curve prepared with a standard substance is required for the quantification.

(2) It is important to discover a low molecular weight inhibition substance for the binding of von Willebrand factor and glycoprotein Ib, and use it as a drug, in
15 view of the treatment and prevention of thromboses. However, no low molecular weight drug has been known so far, which targets the inhibition of the binding of von Willebrand factor and glycoprotein Ib and is reported to have antithrombotic activity.

20 (3) In order to find out such a drug as mentioned in the above (2), large number of binding inhibition experiments must be performed for von Willebrand factor and glycoprotein Ib. However, the conventionally known methods are complicated, and may have problems
25 concerning accuracy and sensitivity.

The present invention has been accomplished from the aforementioned viewpoints, and an object of the

present invention is to provide a method for detecting the binding of von Willebrand factor and glycoprotein Ib in a simple manner, a simple method for measurement of glycocalicin, and a simple method for measurement of a substance that can be an antithrombotic drug of which working point is the inhibition of the binding of von Willebrand factor and glycoprotein Ib, as well as means for use in these measurement methods.

The inventors of the present invention assiduously studied in order to achieve the aforementioned object. That is, a protein expression system based on an animal cell was prepared first for obtaining a chimeric molecule consisting of a partial protein of glycoprotein Ib α chain bound to the Fc region of immunoglobulin molecule (hereinafter referred to as "chimeric protein"). Further, they found that, if von Willebrand factor was immobilized in the presence of botrocetin, the aforementioned chimeric protein, i.e., glycoprotein Ib molecule, specifically bound to the immobilized von Willebrand factor without a binding inducing substance in a liquid phase, and that a binding test can be performed in a simple manner to measure the binding amount by labeling commercially available inexpensive anti-immunoglobulin Fc antibodies or directly labeling the chimeric protein, and thus accomplished the present invention.

That is, the first method according to the present

invention is a method for detecting binding of von
Willebrand factor and glycoprotein Ib or inhibition of
the binding, comprising the steps of immobilizing von
Willebrand factor in a reaction vessel in the presence
5 of a substance inducing the binding of von Willebrand
factor and glycoprotein Ib, and, reacting the
immobilized von Willebrand factor with glycoprotein Ib.

The second method according to the present
invention is a method for detecting binding of von
10 Willebrand factor and glycoprotein Ib or inhibition of
the binding, comprising the steps of binding a chimeric
protein that consists of an Fc region of immunoglobulin
molecule fused at its amino terminus to a partial
protein comprising a von Willebrand factor binding site
15 of glycoprotein Ib α chain at its carboxyl terminus or
the chimeric protein labeled with a labeling substance
to von Willebrand factor immobilized in a reaction
vessel, and detecting the Fc region of the
immunoglobulin molecule or the labeling substance.

20 The third method according to the present
invention is a method for detecting binding of von
Willebrand factor and glycoprotein Ib or inhibition of
the binding, comprising the steps of immobilizing a
chimeric protein that consists of an Fc region of
25 immunoglobulin molecule fused at its amino terminus to a
partial protein comprising a von Willebrand factor
binding site of glycoprotein Ib α chain at its carboxyl

terminus in a reaction vessel, binding von Willebrand factor or labeled von Willebrand factor to the chimeric protein, and detecting bound von Willebrand factor or the labeling substance.

5 In a preferred embodiment of the second method or the third method, when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the
10 reaction vessel.

As the substance that induces the binding of von Willebrand factor and glycoprotein Ib, botrocetin, ristocetin or the both substances can be mentioned.

15 Further, in another embodiment of the second method, von Willebrand factor is immobilized in the reaction vessel in the presence of a substance that induces the binding of von Willebrand factor and glycoprotein Ib.

20 In the first, second and third methods, glyocalicin contained in a sample can be measured by adding the sample to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or the chimeric protein, or prior to the reaction, and detecting inhibition of the binding of von Willebrand
25 factor and glycoprotein Ib or the chimeric protein.

Further, in the first, second and third methods, a substance that inhibits the binding of von Willebrand

factor and glycoprotein Ib can be detected by adding a sample containing a substance to be detected to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or the chimeric protein, or
5 prior to the reaction, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib or the chimeric protein.

The present invention further provides a chimeric protein, which consists of an Fc region of
10 immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.

The present invention also provides a kit for
15 measuring glyco-calicin based on inhibition of a reaction of von Willebrand factor and glycoprotein Ib, which comprises von Willebrand factor and a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein
20 comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.

The present invention further provides a compound which is detected by any of the aforementioned methods for detecting the binding of von Willebrand factor and
25 glycoprotein Ib or inhibition of the binding, and has an activity for specifically inhibiting platelet aggregation involving glycoprotein Ib and von Willebrand

factor in blood plasma and a molecular weight of not more than 2000.

As specific examples of the aforementioned compound, compounds having a structure represented by
5 the formula (I), more specifically, compounds represented by the formula (II) can be mentioned. In the formulae, R^1 and R^2 independently represent H or Cl, and R^3 represents CH_3 or H.

PCT/JP99/00089

The term "chimeric protein" used in the present specification means a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von
5 Willebrand factor binding site of glycoprotein Ib at its carboxyl terminus. Further, the term "glycoprotein Ib" used for the methods of the present invention may refer to glycoprotein Ib itself or the chimeric protein, or the both of them.

10 The term "detection" used in the present specification mainly means finding out a substance or a phenomenon, but it may also mean measurement of amount of the substance or degree of the phenomenon as a result of the finding of the substance or the phenomenon.
15 Further, the term "measurement" mainly means measurement of an amount of substance or a degree of phenomenon, but it may also mean finding out the substance or the phenomenon.

The present invention will be explained in detail
20 hereinafter.

<1> Chimeric protein

The chimeric protein of the present invention is a protein consisting of a partial protein comprising a von
25 Willebrand factor binding site of glycoprotein Ib α chain, which is one of platelet membrane proteins of human or other mammals, bound to an Fc region of a heavy chain (H

chain) of immunoglobulin molecule of mouse, human or other mammals by means of a genetic engineering technique. This chimeric protein can be produced by using cultured cells. In the chimeric protein, the partial protein comprising von Willebrand factor binding site of glycoprotein Iba chain and the Fc region of the immunoglobulin molecule are bound at the carboxyl terminus of the partial protein and the amino terminus of the Fc region.

As an example of the partial protein of glycoprotein Iba chain, there can be mentioned a partial protein having a sequence comprising amino acid residues of from the amino terminus to the aspartic acid residue at the 319th position (amino acid numbers 1-319) of glycoprotein Iba chain molecule. However, since it is considered that von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid numbers 1-293 (V. Vincente et al., *J. Biol. Chem.*, 263, 18473-18479, 1988), and in the sequence of the amino acid numbers 251-285 (V. Vicente et al., *J. Biol. Chem.*, 265, 274-280, 1990), a partial protein containing at least these regions may be sufficient.

Further, the Fc region of immunoglobulin molecule may be derived from any animals, and may be of any subtype, and those that can be purified and/or detected with commercially available polyclonal antibodies and/or monoclonal antibodies, protein A, protein G or the like

may be used. The immunoglobulin heavy chain comprises regions called VH domain, CH1 domain, hinge domain, CH2 domain and CH3 domain (and further CH4 domain in IgE) connected in this order from the amino terminus.

5 For example, the Fc region used for the chimeric protein may be a continuous sequence from the hinge domain to the CH3 domain of the above sequence. However, from the viewpoint that it should be able to be purified and/or detected with commercially available polyclonal
10 antibodies and/or monoclonal antibodies, protein A, protein G or the like, the hinge domain is not essential, and it may partially contain a mutation such as deletion and insertion of one or more amino acid residues.
Further, while the immunoglobulin may be derived from
15 any animals including human and mouse, one derived from mouse can be used, for example. Although the subtype of the immunoglobulin may be any subtype, IgG can be used, for example. The subclass may also be any subclass, and IgG1, IgG2a and so forth can be mentioned, for example.
20 Exemplary amino acid sequences of the chimeric protein of the present invention are shown in SEQ ID NOS: 7 and 14. In SEQ ID NOS: 7 and 14, it is presumed that 16 amino acid residues at the N-terminus constitute a signal peptide.

25 The chimeric protein of the present invention can be produced by allowing expression of a chimeric gene coding for it (chimeric protein gene) in a suitable cell.

A chimeric protein gene can be prepared by obtaining a glycoprotein Iba chain gene and an immunoglobulin heavy chain gene respectively from a cDNA library, genomic library, DNA fragment or the like using genetic
5 engineering techniques or chemically preparing them, and ligating them.

A glycoprotein Iba chain gene can be obtained from, for example, a cDNA library produced by using a phage vector or the like from mRNA of HEL cell, which is a
10 human megakaryocyte cell strain, through reverse transcription PCR using suitable primer DNA designed based on a known DNA sequence of glycoprotein Iba chain gene. Further, a clone containing a glycoprotein Iba chain gene can be obtained from such a cDNA library by
15 performing hybridization using a probe DNA designed based on the known DNA sequence. Alternatively, it can be obtained by excising it from plasmid containing a glycoprotein Iba chain gene registered at ATCC (American Type Culture Collection, pGPIb2.4, deposition number:
20 ATCC65755) with a suitable restriction enzyme.

A gene of immunoglobulin heavy chain can be obtained from, for example, cDNA prepared from mRNA of mouse immunoglobulin producing hybridoma, a cDNA library produced by using a phage vector or the like through
25 reverse transcription PCR using suitable primer DNA designed based on a known DNA sequence of the immunoglobulin heavy chain gene. Further, a clone

containing a mouse immunoglobulin gene can be obtained from such a cDNA library by performing hybridization using a probe DNA designed based on the known DNA sequence.

5 A chimeric protein gene can be obtained by digesting DNA strands of a full length glycoprotein Iba chain gene or a partial sequence thereof and a full length mouse immunoglobulin heavy chain $\gamma 1$ gene or $\gamma 2a$ gene or a partial sequence thereof with a suitable
10 restriction enzyme and then ligating them. The digestion and the ligation of the both genes may be performed so that the ligation product should code for a chimeric protein consisting of an Fc region of immunoglobulin molecule fused at its amino terminus to a
15 partial protein comprising a von Willebrand factor binding site of glycoprotein Iba chain at its carboxyl terminus. Further, extracellular secretion of the chimeric protein is desired, the segment for glycoprotein Iba chain may contain a signal peptide.

20 A chimeric protein gene produced as described above is expressed by using a suitable host-vector system. As the host, animal cells, insect cells and so forth can be mentioned. The vector is not particularly limited so long as it can function as a vector in the
25 host cell, and it is preferable to use an expression vector having a promoter suitable for the host cell. A chimeric protein can be produced by transforming the

host cell with a recombinant vector obtained by inserting a chimeric protein gene into an expression vector, and culturing the transformed cell.

While a chimeric protein produced as described above may be used as it is, it can be readily purified by utilizing the Fc region of immunoglobulin molecule through affinity chromatography using immobilized protein A, protein G, anti-immunoglobulin antibodies and so forth.

10

<2> Method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of this binding

The first method for detecting the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding according to the present invention is characterized in that von Willebrand factor is immobilized in a reaction vessel in the presence of a substance inducing the binding of von Willebrand factor and glycoprotein Ib (henceforth also referred to as "binding inducing substance"), and the immobilized von Willebrand factor is allowed to react with the glycoprotein Ib.

By immobilizing von Willebrand factor in a reaction vessel in the presence of a binding inducing substance, a step of adding a binding inducing substance during the reaction of von Willebrand factor and glycoprotein Ib in a liquid phase can be omitted.

von Willebrand factor can be prepared from human blood according to the method described in H.R. Gralnick et al., *J. Clin. Invest.*, 62, 496 (1978) or the like.

As the binding inducing substance, there can be mentioned botrocetin, ristocetin and so forth, and botrocetin is preferred.

As the reaction vessel in which von Willebrand factor is immobilized, a vessel made of synthetic resin such as polystyrene and polycarbonate or glass may be used. More specifically, a 96-well multi-well plate made of polystyrene and so forth can be mentioned. By injecting a solution containing von Willebrand factor into the aforementioned reaction vessel, von Willebrand factor can be immobilized on a wall surface of the vessel. It is also possible to immobilize collagen on a wall surface of the reaction vessel, and allow von Willebrand factor to bind to the collagen. The conditions for immobilizing von Willebrand factor or collagen to a reaction vessel are not particularly limited so long as they can be immobilized. However, when a vessel made of polystyrene is used, for example, it is preferable to use a neutral solution, preferably at pH 6.8-7.8, more preferably at about pH 7.4.

For the immobilization of von Willebrand factor, while a solution containing von Willebrand factor and a solution containing a binding inducing substance may be separately added to a reaction vessel, it is preferable

to prepare a solution containing both of von Willebrand factor and a binding inducing substance, and add it into the reaction vessel, from the viewpoint of operation efficiency. Further, a reaction vessel in which von
5 Willebrand factor is immobilized is preferably added with a bovine serum albumin solution or the like to block unbound areas on the wall surface.

After von Willebrand factor is immobilized in a reaction vessel, the reaction vessel is washed and then
10 glycoprotein Ib is added. Upon addition of glycoprotein Ib, the binding reaction of von Willebrand factor and glycoprotein Ib is caused. This reaction is attained in a liquid phase. Subsequently, the binding of von Willebrand factor and glycoprotein Ib is detected. This
15 detection can be performed by the method usually used for detection of the binding of von Willebrand factor and glycoprotein Ib.

The second method according to the present invention is a method wherein the binding of von
20 Willebrand factor and glycoprotein Ib or inhibition of the binding is detected by allowing the aforementioned chimeric protein or the chimeric protein labeled with a labeling substance to bind to von Willebrand factor immobilized in a reaction vessel, and detecting the Fc
25 region of the immunoglobulin molecule or the labeling substance. More specifically, a solution containing von Willebrand factor is added to the reaction vessel to

immobilize the von Willebrand factor on a wall surface of the reaction vessel. Then, a solution containing a chimeric protein is added to the reaction vessel to allow the chimeric protein to bind to the immobilized von Willebrand factor. This binding can be induced by the presence of a binding inducing substance in the reaction system of the von Willebrand factor and the chimeric protein. Specifically, when the aforementioned chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to the reaction vessel. For example, von Willebrand factor is immobilized in the reaction vessel in the presence of a binding inducing substance in a manner similar to that of the aforementioned first method, or the binding inducing substance is added at the same time as, or at a time point around the addition of the solution containing the chimeric protein to the reaction vessel.

The chimeric protein binds to the immobilized von Willebrand factor at the von Willebrand factor binding site of glycoprotein Ib contained in the molecule. The detection of the chimeric protein bound to von Willebrand factor as described above can be performed by, for example, detecting the Fc region of the immunoglobulin molecule contained in the molecule. For the detection of the Fc region, a method usually used

for immunoassay can be used.

Specifically, for example, a labeled substance that specifically binds to the Fc region such as protein A, protein G, and anti-immunoglobulin antibodies is
5 added to the reaction vessel, and the label is detected. As the labeling substance, there can be mentioned enzymes such as alkaline phosphatase and peroxidase, biotin, avidin, fluorescent substances such as fluorescein, compounds containing a fluorescent rare
10 earth element such as europium and lanthanoids and so forth. Biotin or avidin is detected by further binding to them another labeling substance bound to avidin or biotin. Enzymes can be detected by adding a suitable substrate to cause an enzymatic reaction and observing
15 visible absorbance, UV absorbance, fluorescence, luminescence etc. Furthermore, fluorescent substances and compounds having a property of emitting fluorescence can be detected based on fluorescence emitted upon irradiation with excitation light.

20 The chimeric protein bound to the immobilized von Willebrand factor can also be detected by using a chimeric protein labeled with a labeling substance beforehand and detecting this labeling substance. The labeling substance and the detecting method therefor may
25 be similar to those mentioned above for use in the detection of the Fc region. When a chimeric protein labeled with a labeling substance is used, a purified

chimeric protein is preferably used.

The purification of the chimeric protein can be attained by using the Fc region of the immunoglobulin molecule through affinity chromatography and so forth as
5 described above.

The third method according to the present invention is a method wherein the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding is detected by allowing von Willebrand
10 factor or von Willebrand factor labeled with a labeling substance to bind to the chimeric protein immobilized in a reaction vessel, and detecting a partial structure of the von Willebrand factor or the labeling substance. More specifically, a solution containing antibodies that
15 bind to a partial structure of the chimeric protein, preferably antibodies that binds to the immunoglobulin Fc region, protein A or protein G is added to a reaction vessel to immobilize them on a wall surface of the reaction vessel. Then, a solution containing a chimeric
20 protein can be added to the reaction vessel to allow the chimeric protein to bind to the immobilized antibodies, protein A, protein G or the like, thereby preparing a reaction vessel on which the chimeric protein is immobilized. Alternatively, a chimeric protein may be
25 directly immobilized in a reaction vessel. Subsequently, a solution containing von Willebrand factor or von Willebrand factor labeled with a labeling substance is

added to the reaction vessel to allow the von Willebrand factor to bind to the immobilized chimeric protein.

This binding can be induced by adding a binding inducing substance to a reaction system of the von Willebrand

5 factor and the chimeric protein. Specifically, when the aforementioned chimeric protein is allowed to bind to the von Willebrand factor, or prior to the binding, a substance that induces the binding of von Willebrand factor and glycoprotein Ib is added to reaction vessel.

10 For example, a binding inducing substance is added at the same time as, or at a time point around the addition of the solution containing von Willebrand factor or von Willebrand factor labeled with a labeling substance to the reaction mixture.

15 The von Willebrand factor binds to the immobilized chimeric protein. The von Willebrand factor that binds to the chimeric protein as described above can be detected, for example, by using antibodies that bind to von Willebrand factor. For the detection of the
20 antibodies bound to the von Willebrand factor, a method usually used for immunoassay can be used. Specifically, for example, there can be mentioned methods utilizing beforehand labeling of the antibodies that bind to von Willebrand factor with an enzyme such as alkaline
25 phosphatase and peroxidase, biotin, avidin, fluorescent substance such as fluorescein, compound containing a fluorescent rare earth element such as europium and

lanthanoids or the like. Biotin or avidin is detected by further binding to them another labeling substance bound to avidin or biotin. Enzymes can be detected by adding a suitable substrate to cause an enzymatic
5 reaction and observing visible absorbance, UV absorbance, fluorescence, luminescence etc. Furthermore, fluorescent substances and compounds having a property of emitting fluorescence can be detected by fluorescence emitted upon irradiation with excitation light.

10 The von Willebrand factor bound to the immobilized chimeric protein can also be detected by using von Willebrand factor labeled beforehand with a labeling substance and detecting this labeling substance. The labeling substance and the detecting method therefor may
15 be similar to those used for the detection of the aforementioned antibodies that bind to von Willebrand factor.

In the aforementioned first, second and third methods, inhibition of the binding of von Willebrand
20 factor and glycoprotein Ib can be detected by comparing a case where a substance inhibiting the binding of von Willebrand factor and glycoprotein Ib (henceforth also referred to as "binding inhibition substance") is added to a reaction vessel at substantially the same time as
25 the addition of glycoprotein Ib (or a chimeric protein) to the reaction vessel or prior to the addition of glycoprotein Ib and a case where the inhibition

substance is not added for the binding of von Willebrand factor and glycoprotein Ib.

Further, in the aforementioned first, second and third methods, a substance inhibiting the binding of von Willebrand factor and glycoprotein Ib can be detected by adding a sample containing a substance to be detected to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib or prior to the reaction and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib. If a standard curve that represents the relation between amount of an inhibition substance and binding of von Willebrand factor and glycoprotein Ib is prepared, the inhibition substance of an unknown amount can be quantified.

No low molecular weight compound has been reported so far, which inhibits the binding of von Willebrand factor and glycoprotein Ib and has antithrombotic activity. The methods of the present invention are extremely simpler compared with the conventional methods, and are also useful for search of such a low molecular compound as mentioned above.

<3> Method and kit for measurement of glycofibrin

In the aforementioned first, second and third methods, glycofibrin can be measured by adding a sample containing glycofibrin to the reaction vessel during the reaction of von Willebrand factor and glycoprotein

Ib or prior to the reaction and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib. If a standard curve that represents the relation between glyocalicin concentration and the binding of von
5 Willebrand factor and glycoprotein Ib is prepared, concentration of glyocalicin in an unknown amount can be measured.

If von Willebrand factor and the chimeric protein are prepared as a kit, the measurement of glyocalicin
10 according to the present invention can conveniently be performed. As such a kit, there can be specifically exemplified a kit comprising von Willebrand factor, a chimeric protein, a binding inducing substance, glyocalicin of a known amount, anti-immunoglobulin
15 antibodies labeled with alkaline phosphatase or the like, a reagent for detecting the label and a washing buffer. As another embodiment, there can be exemplified a kit comprising von Willebrand factor, a chimeric protein labeled with a labeling substance, a binding inducing
20 substance, glyocalicin of a known amount, a reagent for detecting the label and a washing buffer.

<4> Low molecular weight true inhibition substance for binding of von Willebrand factor and glycoprotein Ib

25 By using the method of the present invention for detecting the inhibition of the binding of von Willebrand factor and glycoprotein Ib described in the

above <2>, a low molecular weight true inhibition substance for binding of von Willebrand factor and glycoprotein Ib can be searched (screened). The term "true inhibition substance" used herein means a substance that specifically inhibits platelet aggregation in plasma involving von Willebrand factor and glycoprotein Ib. A substance that inhibits the binding of von Willebrand factor and glycoprotein Ib in a non-specific manner is not a true inhibition substance, even though it may inhibit the binding of von Willebrand factor and glycoprotein Ib, like substances that generally change structures of proteins such as protein denaturing substances and detergents or substances that non-specifically bind to proteins.

A true inhibition substance can be distinguished by measuring inhibitory activity for von Willebrand factor and glycoprotein Ib dependent platelet aggregation in plasma using ristocetin or botrocetin and inhibitory activity for von Willebrand factor and glycoprotein Ib non-dependent platelet aggregation using collagen or adenosine diphosphate (ADP), and comparing them. That is, a compounds which inhibit von Willebrand factor and glycoprotein Ib dependent platelet aggregation (for example, ristocetin-induced platelet aggregation), and does not substantially inhibit von Willebrand factor and glycoprotein Ib non-dependent platelet aggregation (for example, platelet aggregation

induced by collagen or ADP) at the same concentration is a true inhibition substance for the binding of von Willebrand factor and glycoprotein Ib.

The inhibition substance of the present invention
5 . preferably inhibit von Willebrand factor and glycoprotein Ib dependent platelet aggregation at a level of 80% or more, more preferably 90% or more, at a concentration of, for example, 1 mM. Further, if inhibition for von Willebrand factor and a glycoprotein
10 Ib non-dependent platelet aggregation is 30% or less, preferably 25% or less, it can be regarded that there is not substantial inhibition.

The term "low molecular weight" preferably means a molecular weight of 2000 or less, more preferably 1000
15 or less. Further, the inhibition substance of the present invention is preferably one that can exert the activity even if it is not a polymer.

Specific examples of low molecular weight antithrombotic substances screened by the method of the
20 present invention include the compounds of the aforementioned structures, more specifically those compounds mentioned below, which were designated as K17427A, K17427B, K17427C and K17427D. These compounds were found in an actinomycete belonging to the genus
25 *Couchioplanes* (*Couchioplanes* sp. AJ9553 (FERM BP-6612)) as substances that had activity of markedly inhibiting the binding of von Willebrand factor and glycoprotein Ib.

The physicochemical properties of these compounds and an exemplary method for producing them will be explained below.

- 5 (1) Physicochemical properties of K17427A, K17427B, K17427C and K17427D

(i) Physicochemical properties of K17427A

Appearance: yellow amorphous solid.

Molecular formula: $C_{44}H_{44}O_{14}Cl_2$

- 10 Mass spectrometry (high resolution FAB-MS)

Found: 866.2117 (M)⁺

Calcd.: 866.2108

Specific rotation: $[\alpha]_D^{24}$: -60° (c 0.09, THF)

Ultraviolet absorption spectrum: λ_{max} (ε) 235 (57000),

- 15 276 (59500), 427 (25000)

¹H-NMR spectrum (400 MHz, CD₃CO₂D) δ: 7.64 (2H, s), 6.04 (2H, s), 5.38 (2H, s), 3.45 (8H, s), 2.05 (2H, m), 1.28 (6H, d, J=6.8Hz), 1.04 (6H, d, J=6.6Hz), 0.38 (6H, d, J=6.3Hz)

- 20 ¹³C-NMR spectrum (100 MHz, CD₃CO₂D) δ: 205.9 (s), 173.2 (s), 171.8 (s), 162.1 (s), 154.6 (s), 135.5 (d), 134.8 (s), 131.4 (s), 120.8 (s), 120.2 (s), 114.5 (d), 113.1 (s), 111.3 (s), 94.2 (d), 77.6 (s), 55.4 (q), 48.1 (d), 44.3 (d), 35.0 (d), 16.3 (q), 6.7 (q)

- 25 Solubility: easily soluble in dimethyl sulfoxide, pyridine and acetic acid, hardly soluble in water

Structural formula: structure represented by the

aforementioned formula (II)

(ii) Physicochemical properties of K17427B

Appearance: yellow amorphous solid

5 Molecular formula: $C_{43}H_{42}O_{14}Cl_2$

Mass spectrometry (high resolution FAB-MS)

Found: 852.1997 (M)⁺

Calcd.: 852.1952

Specific rotation: $[\alpha]_D^{25}$: -61° (c 0.13, THF)

10 Ultraviolet absorption spectrum (methanol): λ_{max} (ϵ) 235
(41000), 273 (43000), 434 (18500)

1H -NMR spectrum (400MHz, CD_3CO_2D) δ : 7.81 (2H, s), 6.17
(1H, s), 6.14 (1H, s), 5.54 (1H, s), 5.50 (1H, s), 3.62
(3H, s), 3.58 (3H, s), 3.53 (1H, q, $J=7.0Hz$), 3.20 (1H,
15 d, $J=18Hz$), 3.08 (1H, d, $J=18Hz$), 1.20 (3H, d, $J=7.6Hz$),
1.17 (3H, d, $J=6.7Hz$), 1.04 (3H, d, $J=6.7Hz$), 0.97 (3H,
d, $J=6.7Hz$), 0.52 (3H, d, $J=7.0Hz$)

Solubility: easily soluble in dimethyl sulfoxide,
pyridine and acetic acid, hardly soluble in water

20 Structural formula: structure represented by the
aforementioned formula (I) wherein $R^1 = R^2 = Cl$ and $R^3 =$
H

(iii) Physicochemical properties of K17427C

25 Appearance: yellow amorphous solid

Molecular weight (ESI-MS): 799 (M+H)⁺

Ultraviolet absorption spectrum: λ_{max} 234, 281, 418

¹H-NMR spectrum (400 MHz, CD₃OD) δ: 7.59 (2H, d, J=8.4Hz), 7.25 (2H, d, J=8.4Hz), 7.14 (2H, s), 6.05 (2H, s), 5.37 (2H, brs), 3.59 (6H, s), 3.46 (2H, br), 2.12 (2H, m), 1.38 (6H, d, J=5.2Hz), 1.15 (6H, d, J=6.8Hz),
5 0.64 (6H, br)

Structural formula: structure represented by the
aforementioned formula (I) wherein R¹ = R² = H and R³ =
CH₃

10 (iv) Physicochemical properties of K17427D

Appearance: yellow amorphous solid

Molecular weight (ESI-MS): 833 (M+H)⁺

Ultraviolet absorption spectrum: λ_{max} 234, 276, 423

¹H-NMR spectrum (400 MHz, CD₃OD) δ: 7.77 (2H, s), 7.59
15 (1H, d, J=8.4Hz), 7.26 (1H, d, J=8.4Hz), 7.15 (1H, s),
6.09 (1H, s), 6.08 (1H, s), 5.46 (1H, s), 5.37 (1H, brs),
3.61 (3H, s), 3.54 (4H, s), 3.42 (1H, q, J=7.0Hz), 2.12
(2H, m), 1.39 (3H, d, J=6.8Hz), 1.20 (6H, m), 0.63 (3H,
br), 0.50 (3H, d, J=7.0Hz)

20 Structural formula: structure represented by the
aforementioned formula (I) wherein R¹ = Cl, R² = H and R³
= CH₃

(2) Method for producing K17427A, K17427B, K17427C and
25 K17427D

The inhibition substances for the binding of von
Willebrand factor and glycoprotein Ib of the present

invention, K17427A, B, C and D (henceforth referred to simply as "inhibition substances") can be produced by, for example, culturing an actinomycete belonging the genus *Couchioplanes*, for example, *Couchioplanes* sp.

5 AJ9553 (FERM BP-6612) using a liquid or solid nutrient medium containing an assimilable carbon source and nitrogen source. As the carbon source of the nutrient medium, carbohydrates such as glucose, sucrose and starch, glycerol and so forth can be preferably used.

10 As the nitrogen source, naturally occurring substances such as yeast extract, peptone, corn steep powder, soybean flour and cotton seed flour (Pharmamedia), amino acids, inorganic nitrogen-containing compounds such as ammonium sulfate and urea and so forth can be used.

15 The culture for the production of the inhibition substances may be performed as culture with shaking or standing culture using a test tube, flask containing the aforementioned nutrient medium or the like, aeration culture with stirring using a jar fermenter, tank
20 containing the aforementioned nutrient medium or the like and so forth. The culture can be performed usually in the range of 20°C to 40°C, preferably 25°C to 37°C.

Extraction of the inhibition substances from culture broth after completion of the culture can be
25 performed by, for example, extraction with a suitable solvent, adsorption of the inhibition substances on an adsorption resin or the like and subsequent elution with

a suitable solvent. Further, purification of the inhibition substances can be performed by combination of techniques such as solvent extraction, chromatography or reversed phase chromatography and so forth utilizing
5 adsorption resin, activated charcoal, ion exchange resin, silica gel etc.

Specifically, for example, cells of *Couchioplanes* sp. AJ9553 (FERM BP-6612) strain are extracted with acetone, acetone is evaporated from the extract, and the
10 residue is suspended in water. The aqueous suspension is adjusted to pH 2, and then ethyl acetate is added to extract it. The ethyl acetate layer is concentrated under reduced pressure, and the obtained residue is fractionated by anion exchange chromatography. For
15 example, the residue can be dissolved in water-containing methanol, adsorbed on a column filled with DIA ION HP-20 (Mitsubishi Chemical), and eluted with methanol. Then, an inhibition substance is obtained by fractionation of the eluate by HPLC using an ODS column,
20 or fractionation by silica gel TLC. To which one of the compounds mentioned above the obtained inhibition substance corresponds can be determined by examining the aforementioned physicochemical properties.

25

Brief Explanation of the Drawings

Fig. 1 outlines the construction of GPIb-mIgG1Fc

expression system.

Fig. 2 outlines the construction of GPIIb-mIgG2aFc expression system.

Fig. 3 shows binding amount of immobilized von
5 Willebrand factor and a chimeric protein plotted against amount of botrocetin (ELISA).

Fig. 4 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (ELISA).

10 Fig. 5 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (Eu-labeling method).

Fig. 6 shows exemplary quantification of glyocalicin in human plasma (ELISA).

15 Fig. 7 shows exemplary quantification of glyocalicin in human plasma (Eu-labeling method).

Fig. 8 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (method utilizing presence of botrocetin in
20 liquid phase).

Fig. 9 shows activity of inhibition substance for the binding of von Willebrand factor and a chimeric protein (method utilizing immobilized chimeric protein).

Fig. 10 shows activity of inhibition substances
25 K17427A, B, C and D for the binding of von Willebrand factor and a chimeric protein (Eu-labeling method).

Fig. 11 shows activity of inhibition substances

K17427A, B, C and D for the binding of von Willebrand factor and a chimeric protein (^{125}I -labeling method).

Fig. 12 shows inhibitory activity of K17427A for ristocetin induced-platelet aggregation, and ADP- and collagen-induced aggregation.

Best Mode for Carrying out the Invention

The present invention will be explained more specifically in to the following examples.

Example 1: Preparation of chimeric protein gene

<1> Cloning of glycoprotein Ib α chain gene

Cloning of human glycoprotein Ib α chain gene was attained by constructing a cDNA library from human erythroleukemia cells (HEL) according to the method described in Molecular Cloning (Sambrook, J., Fritsch, E.F., Maniatis, T., Molecular Cloning, Cold Spring Harbor Laboratory Press (1989)). That is, human erythroleukemia cells were stimulated by culturing them in a medium containing 160 nM of a phorbol ester (phorbol-12-myristate-13-acetate: PMA) for 48 hours, and then the medium was removed. A guanidinium thiocyanate buffer (4.0 M guanidinium thiocyanate, 0.1 M Tris-HCl (pH 7.5), 1% 2-mercaptoethanol) was added to the cells to suspend the cells in the buffer. The cell suspension was subjected to disruption treatment by using a

Polytron homogenizer (produced by Brinkmann).

Laurylsarcosinate (sodium laurylsarcosinate) was added to the disrupted cell suspension at a final concentration of 0.5%. This solution was centrifuged at
5 5000 x g for 10 minutes to remove the precipitates. The centrifugation supernatant was overlaid on cesium chloride/EDTA solution (5.7 M CsCl, 0.01 M EDTA, pH 7.5) contained in an ultracentrifugation tube and subjected to ultracentrifugation at 100000 x g for 20 hours. The
10 precipitated RNA was collected and purified by ethanol precipitation to obtain total RNA.

The obtained total RNA was loaded on an oligo-dT cellulose column to obtain mRNA. From 10 µg of this mRNA, single-stranded DNA was prepared by using random
15 hexamer oligo DNA as a primer and a reverse transcriptase, and then double-stranded cDNA was prepared by using a DNA polymerase. An *EcoRI* adapter was ligated to this cDNA by using T4 DNA ligase. The cDNA to which the adapter was ligated was subjected to a
20 phosphorylation treatment using T4 polynucleotide kinase, and purified by using a gel filtration column. A λ gt10 arm prepared so that it could be inserted into an *EcoRI* restriction site (produced by Stratagene) was ligated to this DNA using T4 DNA ligase. This recombinant DNA was
25 packaged in phage to obtain a cDNA library.

Escherichia coli NM514 was infected with this phase. Plaque hybridization was performed for the

produced phage plaques by using oligo DNA (SEQ ID NO: 1) end-labeled with a radioisotope (^{32}P) as a probe. That is, the produced phage plaques were transferred to a nitrocellulose filter, and DNA was denatured with an
5 alkaline denaturation solution (0.5 M sodium hydroxide, 1.5 M sodium chloride). The filter was neutralized with a neutralization solution (0.5 M Tris-HCl, pH 7.0, 1.5 M sodium chloride), and heated at 80°C for 2 hours to immobilize the DNA on the filter. Synthesized DNA
10 (chemically synthesized by using a DNA synthesizer Model 380A produced by Perkin-Elmer Applied Biosystems) was labeled at the 5' end of the DNA with γ - ^{32}P -ATP with the aid of T4 DNA kinase (produced by Takara Shuzo), and used as probe DNA. The nucleotide sequence of the
15 aforementioned oligo DNA was designed based on the nucleotide sequence of a known human glycoprotein Iba chain gene (J.A. Lopez et al., *Proc. Natl. Acad. Sci. USA*, 84, 5615-5619 (1987)).

The nitrocellulose filter (diameter: 132 mm) on
20 which phage plaque DNA was transferred was immersed in 4 ml of a hybridization buffer (0.9 M sodium chloride, 0.09 M sodium citrate (pH 7.0), 0.5% sodium laurylsulfate, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin, 100 $\mu\text{g/ml}$ heat-denatured
25 salmon sperm DNA) containing the probe corresponding to 1×10^6 cpm (count per minute) per one filter, and allowed to hybridize at 42°C for 16 hours. The filter

was washed three times with 1 x SSC (0.875% sodium chloride, 0.441% sodium citrate, pH 7.0) and 0.1% sodium laurylsulfate solution at 37°C for 30 minutes to remove the probe non-specifically adsorbed on the filter.

- 5 After the filter was dried, radioautography was performed by using an X-ray film. As a result, four strains of positive clones were obtained.

The phage was isolated from each positive clone, and *Escherichia coli* NM514 was infected with the isolated phage and proliferated. Then, phage DNA from each clone was purified by cesium chloride density gradient ultracentrifugation. This phage DNA was digested with a restriction enzyme *EcoRI*, and DNA was purified by agarose electrophoresis. This purified DNA was inserted into the *EcoRI* site of pBluescriptSK- (produced by Stratagene) and used for transformation of the *Escherichia coli* XLIIblue (produced by Stratagene) to obtain a transformant. Plasmid was prepared from the transformant by the alkali SDS method, and the nucleotide sequence of the plasmid DNA was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. It was confirmed that one strain among the obtained positive clones contained cDNA of 2.4 kb, and it was the clone having the full length of human glycoprotein Iba gene reported by J.A. Lopez et al. (*Proc. Natl. Acad. Sci.*

USA, Vol. 84, pp.5615-5619 (1987)). This plasmid was designated as pBluescriptGPIbAlpha.

<2> Cloning of gene coding for Fc region of
5 immunoglobulin (γ 1 origin)

The gene for the Fc region of mouse immunoglobulin γ 1 was obtained by extracting total RNA from a mouse hybridoma cell strain MB40.3 and performing reverse transcription PCR. That is, from 10 ml of culture broth
10 of MB40.3 cells, the cells were collected by centrifugation, and the cells were lysed with ISOGEN (1 ml, produced by Nippon Gene). The lysate was subjected to syringing using an injection needle of 18G. The
lysate was left for 5 minutes, then added with 200 μ l of
15 chloroform and mixed. The mixture was left stand for 2 minutes and then centrifuged (15000 rpm, 15 minutes) to recover an aqueous phase. The aqueous phase was added with 500 μ l of 2-propanol, mixed, left stand for 5 minutes and centrifuged (15000 rpm, 15 minutes) to
20 precipitate the total RNA. The total RNA was washed with 75% ethanol and dissolved in 100 μ l of sterilized water.

cDNA was prepared by using 3 μ g (20 μ l) of MB40.3 cell total RNA prepared as described above as a template
25 and using random primers and reverse transcriptase (Superscript II produced by GIBCO). The cDNA was amplified by PCR using the primers of SEQ ID NOS: 2 and

3, digested with HindIII and BamHI, purified by agarose gel electrophoresis, and ligated to pGEM-3Zf (produced by Promega) digested with HindIII and BamHI.

Escherichia coli XLIIblue (produced by Stratagene) was transformed with the obtained recombinant DNA. One of the obtained transformants was cultured. Plasmid was prepared by the alkali SDS method, and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. The obtained nucleotide sequence of the gene fragment for the Fc region of mouse immunoglobulin $\gamma 1$ is shown in SEQ ID NO: 4. This plasmid was designated as pGEMmIgG1Fc.

15

<3> Preparation of plasmid expressing chimeric protein (GP1b-mIgG1Fc)

A chimeric protein comprising the human glycoprotein Ib gene and the Fc region of mouse immunoglobulin $\gamma 1$ obtained as described above, which were fused together, was prepared as follows.

First, the plasmid pBluescriptGP1Alpha containing the glycoprotein Ib α chain gene was digested with restriction enzymes EcoRI and XbaI, and separated by agarose gel electrophoresis to recover DNA of about 1000 bp, which corresponded to the N-terminus region of glycoprotein Ib α chain gene. This was inserted into the

EcoRI-XbaI site of pBluescriptSK- (produced by Stratagene) to prepare plasmid pBluescriptGPIbEX.

Separately, the plasmid pGEMmIgG1Fc containing the partial gene of mouse immunoglobulin γ 1 obtained as described above was digested with a restriction enzyme XbaI and separated by agarose gel electrophoresis to recover the IgG1Fc gene of 700 bp. This DNA was ligated to pBluescriptGPIbEX digested with a restriction enzyme XbaI and subjected to CIAP treatment to obtain plasmid pBluescriptGPIbIgG1FcFH. The protein encoded by this gene was designated as GPIb-mIgG1Fc, of which gene sequence and amino acid sequence are shown in SEQ ID NOS: 6 and 7, respectively. In SEQ ID NO: 6, it is presumed that the 16 amino acid residues of the N-terminus constitute a signal peptide.

Further, pBluescriptGPIbIgG1FcFH was digested with a restriction enzyme XhoI, and DNA coding for GPIbFcFH was separated by agarose gel electrophoresis. This DNA was inserted into the XhoI site of an expression vector for animal cells pSD(X) to obtain an expression vector pSDGPIbIgG1FcFH, in which the GPIb gene was inserted downstream from a promoter. The outline of the aforementioned procedure is shown in Fig. 1.

Escherichia coli XLIIblue (*Escherichia coli* AJ13434) harboring the plasmid pSDGPIbIgG1FcFH was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology,

Ministry of International Trade and Industry on April 2, 1998, and given an accession number of FERM P-16749.

This was transferred to an international deposit under the provision of the Budapest Treaty on January 11, 1999, and given an accession number of FERM BP-6619.

<4> Cloning of gene coding for Fc region of immunoglobulin (γ 2a origin)

The gene of the Fc region of mouse immunoglobulin γ 2a was obtained by extracting total RNA from a mouse hybridoma cell strain W6/32 and performing reverse transcription PCR. That is, from 10 ml of culture broth of W6/32 cells, the cells were collected by centrifugation, and the cells were lysed with ISOGEN (1 ml, produced by Nippon Gene). The lysate was subjected to syringing using an injection needle of 18G. The lysate was left for 5 minutes, then added with 200 μ l of chloroform and mixed. The mixture was left stand for 2 minutes and then centrifuged (15000 rpm, 15 minutes) to recover an aqueous phase. The aqueous phase was added with 500 μ l of 2-propanol, mixed, left stand for 5 minutes and then centrifuged (15000 rpm, 15 minutes) to precipitate the total RNA. The total RNA was washed with 75% ethanol and dissolved in 100 μ l of sterilized water.

cDNA was prepared by using 3 μ g (20 μ l) of the W6/32 cell total RNA prepared as described above as a

template and using random primers and reverse transcriptase (Superscript II produced by GIBCO). The cDNA was amplified by PCR using primers having nucleotide sequences of SEQ ID NOS: 8 and 9, digested with *Hind*III and *Bam*HI, purified by agarose gel electrophoresis, and ligated to pGEM-3Zf (produced by Promega) digested with *Hind*III and *Bam*HI. *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant DNA. One of the obtained transformants was cultured. Plasmid was prepared by the alkali SDS method and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. The obtained nucleotide sequence of the gene fragment for the Fc region of mouse immunoglobulin γ 2a is shown in SEQ ID NO: 10. This plasmid was designated as pGEMmIgG2aFc.

<5> Preparation of plasmid expressing chimeric protein (GP1b-mIgG2aFc)

A chimeric protein gene comprising the human glycoprotein Ib gene and the Fc region of mouse immunoglobulin γ 1 obtained as described above and fused together was prepared as follows.

First, the plasmid pBluescriptGP1Alpha containing the glycoprotein Ib α chain gene was digested with

restriction enzymes *EcoRI* and *XbaI*, and separated by agarose gel electrophoresis to obtain a *KpnI*-*XbaI* DNA fragment containing the sequence of glycoprotein Ib gene for the sequence of from the N-terminus to the 319th aspartic acid.

Further a gene fragment of the Fc region of mouse immunoglobulin $\gamma 2a$ having an *XhoI* site at the 5' end side and an *XbaI* site at the 3' end side was produced by PCR (annealing temperature: 55°C, 30 cycles) using the plasmid pGEMmIgG2aFc containing the partial gene of mouse immunoglobulin $\gamma 2a$ obtained as described above, two kinds of synthetic primers having the nucleotide sequences shown in SEQ ID NOS: 9 and 12 and PFU (produced by Stratagene). This gene fragment was digested with *XbaI* and *XhoI*, then purified by agarose gel electrophoresis and ligated to pBluescriptSK- digested with *XbaI* and *XhoI*. *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant plasmid. Plasmid was prepared from the obtained transformant by the alkali SDS method, and the nucleotide sequence thereof was determined by the dideoxy method using a DNA sequencer Model 377 produced by Perkin-Elmer Applied Biosystems according to the protocol attached to the instrument. As a result, it was confirmed to have a nucleotide sequence corresponding to the nucleotide sequence shown in SEQ ID NO: 10 of which 6 nucleotides at the 5' end was replaced

with TCTAGAC and 6 nucleotides at the 3' end was eliminated. This plasmid was designated as pBluescriptmIgG2a. This plasmid was digested with *Xba*I and *Xho*I, and purified by agarose gel electrophoresis to obtain a *Xba*I-*Xho*I fragment of the Fc region gene of mouse immunoglobulin γ 2a..

The *Kpn*I-*Xba*I fragment of human glycoprotein Ib gene and the *Xba*I-*Xho*I fragment of Fc region gene of mouse immunoglobulin γ 2a obtained as described above were ligated to pBluescriptSK- digested with *Kpn*I and *Xho*I, and *Escherichia coli* XLIIblue (produced by Stratagene) was transformed with the obtained recombinant plasmid. One of the obtained transformants was cultured, and plasmid was prepared by the alkali SDS method to obtain plasmid containing a gene coding for a protein (chimeric protein) comprising the N-terminus side region of glycoprotein Ib (amino acid numbers 1-319, including a signal peptide) and the Fc region of mouse immunoglobulin γ 2a bound together (SEQ ID NO: 13). This plasmid was designated as pBluescriptGPIbFc2a, and the encoded chimeric protein corresponding to the gene was especially designated as GPIb-mIgG2aFc, of which amino acid sequence was shown in SEQ ID NO: 14. In SEQ ID NO: 14, it is presumed that 16 amino acid residues of the N-terminus constitute a signal peptide. *Escherichia coli* XLIIblue (*Escherichia coli* AJ13432) harboring the plasmid pBluescriptGPIbFc2a was deposited at the

National Institute of Bioscience and Human-Technology,
Agency of Industrial Science and Technology, Ministry of
International Trade and Industry on March 19, 1998, and
given an accession number of FERM P-16719. Then, it was
5 transferred to an international deposit under the
provisions of the Budapest Treaty on January 11, 1999,
and given an accession number of FERM BP-6618.

pBluescriptGPIbFc2a was digested with *Xho*I, and
purified by agarose electrophoresis. This *Xho*I fragment
10 containing a gene of the chimeric protein was ligated to
the *Xho*I site of the same animal cell expression vector
pSD(x) as the above <3> to obtain plasmid pSDGPIbFc2a.
Further, pGPIbFcbluescript was digested with *Eco*RI and
*Xho*I, and the *Eco*RI-*Xho*I fragment containing the
15 chimeric protein gene was inserted into the *Eco*RI-*Xho*I
site of expression vector pMikNeo(+) for animal cells
(kindly provided by Dr. K. Maruyama, the Institute of
Medical Science, the University of Tokyo) having SR α
promoter (K. Maruyama and Y. Takebe et al., *Medical*
20 *Immunology*, 20, 27-32, 1990) to obtain plasmid
pMikGPIbFc. The outline of the procedure used for
obtaining pMikGPIbFc is shown in Fig. 2.

Example 2: Production of chimeric protein (GPIb-mIgG1Fc)
25 using animal cells

Cells producing the chimeric protein were produced
as follows. CHOdhfr⁻ cells were cultured by using D-MEM

medium (10 ml, produced by GIBCO) containing 10% fetal bovine serum at 37°C under 5% CO₂ at a density of 5 x 10⁵ cells per 10-cm dish. The cells were transfected with pSDGPiB-IgG1Fc prepared as described in Example 1
5 <3>. The transfection was performed by using calcium phosphate as described below. That is, about 10 µg per 10-cm dish of pSDGPiB-IgG1Fc was added to 0.5 ml of BES buffer (pH 6.96) containing 0.125 M calcium chloride, uniformly added dropwise to a dish, and incubated
10 overnight at 35°C under 3% CO₂. Then, the dish was washed twice with PBS, and further incubated in α-MEM medium not containing nucleic acid at 37°C for about 24 hours under 5% CO₂. The cells transfected as described above were further cultured in α-MEM medium not
15 containing nucleic acids, but containing 0.05 µM methotrexate (MTX) and 10% fetal bovine serum to obtain chimeric protein producing cells.

The chimeric protein producing cells obtained as described above were cultured in an F175 cell culture
20 flask containing α-MEM medium not containing nucleic acid, but containing 0.05 µM methotrexate (MTX) and 10% fetal bovine serum, until about 60% confluent. Then, the medium was exchanged with a serum-free medium, ASF104 medium (produced by Ajinomoto), containing 0.05
25 µM methotrexate (MTX), and the culture supernatant was collected four days later.

Example 3: Production of chimeric protein (GPIb-
mIgG2aFc) using animal cells

Cells producing the chimeric protein were produced as follows. CHOK1 cells were cultured by using D-MEM
5 medium (10 ml, produced by GIBCO) containing 10% fetal bovine serum at 37°C under 5% CO₂ at a density of 5 x 10⁵ cells per 10-cm dish. The cells were transfected with pMikGPIbFc prepared in Example 1. The transfection was performed by the calcium phosphate method as
10 described below. That is, about 10 µg per 10-cm dish of pMikGPIbFc was added to 0.5 ml of BES buffer (pH 6.96) containing 0.125 M calcium chloride, uniformly added dropwise to a dish, and incubated overnight at 35°C under 3% CO₂. Then, the dish was washed twice with PBS,
15 and further incubated in D-MEM medium at 37°C for about 24 hours under 5% CO₂. The cells transfected as described above were further cultured in D-MEM medium containing G418 (850 µg/ml) and 10% fetal bovine serum to obtain chimeric protein producing cells, which were
20 G418 resistant cells.

The chimeric protein producing cells obtained as described above were cultured in an F175 cell culture flask containing D-MEM medium containing G418 (800 µg/ml) and 10% fetal bovine serum until about 60%
25 confluent. Then, the medium was exchanged with a serum-free medium, ASF104 medium (produced by Ajinomoto), containing G418 (800 µg/ml), and the culture supernatant

was collected four days later.

The collected culture supernatant was centrifuged to remove the solid, and then 160 ml of the supernatant was passed through a Protein A Hitrap (1 ml, produced by Pharmacia) column washed with 20 mM phosphate buffer (pH 7.0) so that the chimeric protein should be adsorbed on the column. The column was sufficiently washed with 20 mM phosphate buffer (pH 7.0), and then eluted with 0.1 M citrate buffer (pH 4.5). The elution of the chimeric protein was performed with detection by a UV monitor at 280 nm, and chimeric protein eluted fractions were immediately neutralized by adding 1 M Tris-HCl buffer (pH 8.5). As a result of SDS electrophoresis, the chimeric protein obtained as described above was found to be a protein having a molecular weight of about 80 kDa as a reduced form and a molecular weight about twice as much as that of the reduced form as non-reduced form.

Example 4 Detection of binding of chimeric protein to
immobilized mixture of von Willebrand factor and
botrocetin

<1> Detection of binding of chimeric protein by ELISA using anti-mouse IgG-Fc antibodies

Botrocetin was obtained from 1 g of lyophilized product of crude venom of *Botrops jararaca* (produced by Sigma) by purification according to the method reported by Read (M.S. Read et al., *Proc. Natl. Acad. Sci. USA.*,

75, 4514-4518, 1978).

Immobilization of a mixed solution of von Willebrand factor and botrocetin on a 96-well multititer plate was attained as follows. First, a physiological saline solution of von Willebrand factor (250 µg/ml) and a physiological saline solution of botrocetin (500 µg/ml), which were prepared in a conventional manner, were appropriately diluted, and mixed at the concentration ratios shown in Fig. 2. Then, 50 µl of each mixture was added to each well of a 96-well multititer plate (Maxisorp, produced by Nunc). The plate was left stand overnight at 4°C, and then each well was washed once with a physiological Tris buffer (150 µl, 20 mM Tris-HCl (pH 7.4), 0.15 M sodium chloride; Tris buffered saline, referred to as "TBS" hereinafter). Then, each well was added with 100 µl of TBS containing 10% BSA (bovine serum albumin), left stand for about 3 hours, and washed 3 times with TBS to obtain a von Willebrand factor immobilized plate.

Each well of the plate on which von Willebrand factor was immobilized in the presence of botrocetin as described above was added with 25 µl of TBS containing 1% BSA and 25 µl of a solution prepared by diluting 8 times the culture supernatant of the chimeric protein (GPIb-mIgG1Fc) producing cells obtained by using the serum free medium with TBS containing 1% BSA, incubated at room temperature for 1 hour, and washed 3 times with

TBS (150 μ l) containing 0.05% Tween-20. Anti-mouse IgG-Fc goat polyclonal antibodies (Catalog No. 55482, produced by Organon Teknika) were biotinylated by using Biotin Labeling Kit (Catalog No. 1418165, produced by
5 Boehringer Mannheim) according to the protocol attached to the kit. 50 μ l of 0.1% BSA/TBA solution containing about 2 μ g/ml of the above biotinylated anti-mouse IgGFc antibodies was added to each well of the plate, and incubated at room temperature for 1 hour. Further, each
10 well was washed 3 times with TBS (150 μ l) containing 0.05% Tween-20, added with 50 μ l of a solution of the reagent (mixture of biotinylated alkaline phosphatase and streptavidin) contained in VECTASTAIN ABC kit (kit for biotin detection, Alkaline phosphatase standard,
15 Catalog No. AK-5000, produced by Vector Laboratories), which solution was prepared in 0.1% BSA/TBS at 1/5 concentration of that used in the method specified in the manual, and incubated at room temperature for 1 hour. Each well was washed 5 times with TBS (150 μ l)
20 containing 0.05% Tween-20, and added with 100 μ l of 100 mM NaHCO₃ solution containing 10 mM MgCl₂, in which p-nitrophenylphosphate was dissolved at 1 mg/ml, to carry out the color development reaction for about 1 hour. After the color development, absorbance at 405 nm was
25 measured. As shown in Fig. 3, the binding of the chimeric protein was observed in a botrocetin and von Willebrand factor amount dependent manner.

<2> Detection of chimeric protein binding using europium (Eu) labeling method

The chimeric protein (GPIb-mIgG2aFc) solution
5 purified by the Protein A column, which was obtained in
Example 3, was dialyzed against physiological saline.
The solution of about 200 µg/1.5 ml was concentrated to
780 µl (concentration of about 250 µg/ml) by
ultrafiltration using Centricon-10 (produced by Amicon).
10 500 µl of the concentrated solution (containing about
125 µg of GPIb-mIgG2aFc) was added with 50 µl of 0.5 M
NaHCO₃, then added with 50 µl of a solution obtained by
dissolving 0.2 mg of Eu-Labeling Reagent (europium DTTA-
isothiocyanate as compound, DELFIA 1244-302, produced by
15 Wallac) in 250 µl of physiological saline, and stirred
at room temperature for about 40 hours to allow the
reaction of europium DTTA-isothiocyanate.

The above reaction mixture was subjected to gel
filtration using HiLoad16/60 Superdex 75pg (inner
20 diameter of 16 mm, length of 60 cm, produced by
Pharmacia) to separate the unreacted reagent and the
chimeric protein. The gel filtration was performed at a
flow rate of 1 ml/minute by using physiological saline
as the eluant. The chimeric protein labeled with Eu was
25 recovered in fractions of the elution volume of 40 to 48
ml. The protein was quantified by using a protein assay
kit (Protein Assay, produced by Bio-Rad) and IgG as a

standard substance. As a result, the concentration of the labeled chimeric protein in the eluted solution had a concentration of 6.4 µg/ml. Hereafter, the following experiments were conducted by using this value as the
5 chimeric protein concentration.

The binding of the europium (Eu) labeled chimeric protein and the von Willebrand factor immobilized in the presence of botrocetin prepared as described above was detected as follows. According to the method mentioned
10 in Example 4 <1>, a mixed solution (TBS) containing 2.5 µg/ml of von Willebrand factor and 2.5 µg/ml of botrocetin was added to each well of a 96-well multititer plate (microtitration plate DELFIA, 1244-550, produced by Wallac), immobilized overnight and subjected
15 to washing, blocking and washing to prepare a von Willebrand factor immobilized plate.

Each well of the above plate was added with 25 µl of an assay buffer containing 0.5% BSA (Assay Buffer, Wallac DELFIA 1244-106, produced by Wallac, Composition:
20 0.5% BSA, 0.05% bovine γ-globulin, 0.01% Tween-40, 20 µM DTPA (diethylenetriamine tetraacetic acid), 50 mM Tris-HCl buffered saline (pH 7.8), 0.05% sodium azide) or the recombinant AS1051 (in which Cys81 was replaced with Ala, N. Fukuchiet al., WO 95/08573) at a final concentration
25 of 20 µg/ml as the binding inhibition substance, further added with 25 µl of a solution of europium (Eu) labeled chimeric protein in the same assay buffer (100 ng/ml),

shaken for 1 minute for stirring, and then left stand at room temperature for 2 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with 100 μ l of a fluorescence enhancement buffer (Enhancement buffer, 1244-104, produced by Wallac, Composition: 15 μ M β -NTA (2-naphthoyltrifluoroacetone), 50 μ M TOPO (tri-n-octylphosphine oxide), 1 g/L Triton X-100, 100 mM acetic acid/potassium hydrogen phthalate buffer), and shaken for 1 minute for stirring. Then, the amount of europium (Eu) was measured by using a DELFIA Research fluorophotometer (1230 ARCUS Fluorometer, produced by Wallac, measurement time: 1 second). The measured values (with addition or no addition of the binding inhibition substance) and CV value (deviation, %) are shown in Table 1.

Table 1: Measured value and CV value (%) by Eu-labeling method

Average value of count in control (n=80)	26668 cpm
CV value (%)	6.75%
Average value of count with addition of AS1051 (10 μ g/ml) (n=6)	935 cpm
S/N ratio	28.5

Example 5: Detection of inhibition by binding inhibition substance for binding of von Willebrand factor and chimeric protein

<1> Detection of inhibition for binding of chimeric

protein by ELISA using anti-mouse IgG-Fc antibodies

The detection was carried out in the same manner as that of Example 4 <1> except that von Willebrand factor was immobilized by using a mixed solution (TBS) containing 2.5 µg/ml of von Willebrand factor and 2.5 µg/ml of botrocetin, and a binding inhibition substance of which inhibitory activity was desired to be measured was added to the reaction of the immobilized von Willebrand factor and the culture supernatant of the chimeric protein producing cells.

As the binding inhibition substance, AJvW-2, which is an anti-human von Willebrand factor monoclonal antibody, and a human glycoprotein Ib binding peptide derived from snake venom of *Crotalus horridus horridus* were used.

The hybridoma producing AJvW-2 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on August 24, 1994, and given an accession number of FERM P-14487. Then, it was transferred to an international deposit under the provisions of the Budapest Treaty on September 29, 1995, and given an accession number of FERM BP-5248 (refer to WO96/17078). AJvW-2 can be obtained by culturing this hybridoma.

The aforementioned human glycoprotein Ib binding

peptide corresponded to a single chain peptide obtained from a multi-mer peptide derived from snake venom of *Crotalus horridus horridus* (AS1051) in which 81-cysteine residue was replaced with an alanine residue (variant type AS1051). The variant type AS1051 was obtained by modifying the gene coding for AS1051 so that the 81-cysteine residue should be replaced with an alanine residue, and expressing it in *Escherichia coli*. *E. coli* HB101/pCHA1 (*E. coli* AJ13023) harboring pCHA1 was deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (postal code: 305, 1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan) on August 12, 1994 as an international deposit under the provisions of the Budapest Treaty, and given an accession number of FERM BP-4781 (refer to WO95/08573). AS1051 itself is also a human glycoprotein Ib binding peptide, and it can be detected in the same manner as that for the variant type AS1051.

The inhibitory activities of AJvW-2 and the variant type AS1051 for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 4.

<2> Detection of inhibition for binding of chimeric protein by europium (Eu) labeling method

The detection was carried out in the same manner

as that of Example 4 <2> except that von Willebrand factor was immobilized by using a mixed solution (TBS) containing 2.5 µg/ml of von Willebrand factor and 2.5 µg/ml of botrocetin, and a binding inhibition substance of which inhibitory activity was desired to be measured was added to the reaction of the immobilized von Willebrand factor and the chimeric protein labeled with europium (Eu).

As the binding inhibition substance, AJvW-2, which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051. The inhibitory activities of the both substances for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 5.

15

Example 6: Detection of glyocalicin in plasma

<1> Detection of glyocalicin by ELISA using anti-mouse IgG-Fc antibodies

Human plasma was prepared by collecting blood from healthy volunteers using an injection needle of 18G, adding 1/10 volume of 3.8% aqueous sodium citrate solution to the blood, and centrifuging the mixture at 3000 x rpm for 10 minutes to separate a supernatant.

Each human plasma collected independently from three volunteers was successively diluted 2-fold (8 times of dilution in total), and 25 µl of the plasma was added to each well of the plate. Each well of the plate

was further added with 25 μ l of a solution prepared by diluting 8-fold a culture supernatant obtained from culture of the chimeric protein producing cells in a serum-free medium with TBS containing 0.1% BSA, and
 5 incubated at room temperature for 1 hour. The subsequent reactions and color development were performed in the same manner as Example 5 <1>, and the average values of the results are shown in Fig. 6.

The blood concentration of glyocalicin in healthy
 10 people was reported to be about 2 μ g/ml. On the other hand, the glyocalicin concentration showing 50% binding inhibition in this detection system was about 400 ng/ml. From this fact, it was considered that a glyocalicin amount of 60 ng/ml or more could sufficiently be
 15 measured in view of the linearity of the plot.

<2> Detection of glyocalicin using chimeric protein labeled with europium (Eu)

Each human plasma independently prepared in the
 20 same manner as the above <1> were successively diluted 2-fold with TBS (8 times of dilution in total), and 25 μ l each of the diluted plasma was added to each well of a von Willebrand factor immobilized plate prepared in the same manner as in Example 5 <1> (microtitration
 25 plate DELFIA, 1244-550, produced by Pharmacia Biotech, was used as the base plate). Further, 25 μ l a solution of the chimeric protein labeled with europium (Eu) in

assay buffer prepared in the same manner as in Example 4
<1> (100 ng/ml, Assay Buffer; 1244-106, produced by
Pharmacia Biotech) was added to each well of the plate
for reaction. The subsequent washing and measurement
5 were performed in the same manner as in Example 5 <2>,
and the average values of the results are shown in Fig.
7.

The blood concentration of glyocalicin in healthy
people was reported to be about 2 µg/ml. On the other
10 hand, the glyocalicin concentration showing 50% binding
inhibition was about 60 ng/ml in this detection system.
From this fact, it was considered that a glyocalicin
amount of 30 ng/ml or more could sufficiently be
measured.

15

Example 7: Detection of binding of chimeric protein to
immobilized von Willebrand factor in the presence of
botrocetin and detection of binding inhibition by
binding inhibition substance

20 <1> Detection of binding of chimeric protein

A TBS solution (50 µl) containing human von
Willebrand factor (2.5 µg/ml) was added to each well of
a 96-well plate, and the von Willebrand factor was
immobilized as a solid phase overnight at 4°C. Each
25 well was washed once with TBS (150 µl) and blocked with
TBS containing 5% BSA for about 3 hours. Each well of
the plate was washed twice with TBS (150 µl), and then

added with 25 μ l of an assay buffer (Assay Buffer, Wallac DELFIA 1244-106, produced by Wallac, composition was mentioned in Example 4 <2>) or a recombinant AS1051 (in which Cys81 was replaced with Ala) at a final

5 concentration of 20 μ g/ml, further added with the assay buffer (25 μ l) containing the europium (Eu)-labeled chimeric protein prepared in Example 4 <2> (100 ng/ml) and botrocetin (500 ng/ml), and left stand at room temperature for 3 hours. Each well of the plate was

10 washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with 100 μ l of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 <2>), and shaken for 1 minute. Then, the amount of europium (Eu)

15 was measured by using a 1420 ARVO multi-label counter (produced by Wallac, measurement time: 1 second). The measured values (with no addition of sample or addition of the inhibition sample) and CV value (deviation, %) are shown in Table 2.

20

Table 2: Measured value and CV value (%) obtained by method utilizing presence of botrocetin in liquid phase

Average value of count in control (n=80)	70220 counts
CV value (%)	8.2%
Average value of count with addition of AJvW-2 (10 μ g/ml) (n=16)	2014 counts
S/N ratio	35

<2> Measurement of inhibition for binding of chimeric

protein by inhibition substance

The measurement was performed in the same manner as in Example 7 <1> except that a binding inhibition substance of which inhibition activity was desired to be measured was added.

As the inhibition substance, AJvW-2 mentioned in Example 5 <1>, which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051 similarly mentioned in Example 5 <1>, which is a human glycoprotein Ib binding protein, were used.

The inhibitory activities for the binding of the chimeric protein (i.e., glycoprotein Ib) of AJvW-2 and the variant type AS1051 are shown in Fig. 8.

Example 8: Detection of binding of von Willebrand factor to immobilized chimeric protein in the presence of binding inducing substance and detection of binding inhibition by binding inhibition substance

<1> Detection of binding using botrocetin

First, 500 μ l of a solution of human von Willebrand factor in physiological saline (300 μ g/ml) was added with 50 μ l of 0.5 M NaHCO_3 , then added with 50 μ l of a solution formed by dissolving 0.2 mg of Eu-labeling Reagent (Europium DTTA-isothiocyanate as compound, DELFIA 1244-302, produced by Wallac) in 250 μ l of physiological saline, and allowed to react at room temperature for about 40 hours with stirring.

The above reaction mixture was subjected to gel filtration using HiLoad 16/60 Superdex 75pg (inner diameter of 16 mm, length of 60 cm, produced by Pharmacia) to separate unreacted reagents and von Willebrand factor. The gel filtration was performed at a flow rate of 1 ml/minute by using physiological saline as eluate. The human von Willebrand factor labeled with Eu was collected in fractions of 40 to 48 ml of elution volume.

10 The binding of von Willebrand factor labeled with europium (Eu), which was prepared as described above, and the immobilized chimeric protein in the presence of botrocetin was detected as follows. First, 50 μ l of a solution of anti-mouse immunoglobulin polyclonal
15 antibodies (Catalog No. 55482, produced by Organon Teknika, 1 μ g/ml) in 0.1 M sodium carbonate buffer (pH 9.6) was added to each well of a 96-well multititer plate (microtitration plate DELFIA, 1244-550, produced by Wallac), and the antibodies were immobilized
20 overnight. Then, each well was washed, blocked with TBS (100 μ l) containing 5% BSA, and washed 3 times with TBS (150 μ g/ml). Further, 50 μ l of a solution of the chimeric protein (0.5 μ g/ml) in TBS was added to each well and left stand at room temperature for 3 hours to
25 allow the chimeric protein to bind to the immobilized anti-mouse immunoglobulin antibodies. Thus, a chimeric protein immobilized plate was prepared.

Each well of the chimeric protein immobilized plate was washed 3 times with TBS (150 μ l) containing 0.05% Tween-20. Then, in the same manner as mentioned in Example 4 <1>, each well of the plate was added with
5 25 μ l of an assay buffer (Assay Buffer, 1244-106, produced by Wallac, composition was mentioned in Example 4 <2>) or a recombinant AS1051 (in which Cys81 was replaced with Ala) as the inhibition substance at a final concentration of 20 μ g/ml, further added with the
10 assay buffer (25 μ l) containing the europium (Eu)-labeled von Willebrand factor (500 ng/ml) and botrocetin (500 ng/ml), and left stand at room temperature for 3 hours. Each well of the plate was washed 5 times with TBS (150 μ l) containing 0.05% Tween-20, then added with
15 100 μ l of a fluorescence enhancement buffer (Enhancement solution, 1244-104, produced by Wallac, composition was mentioned in Example 4 <2>), and shaken for 1 minute. Then, the amount of europium (Eu) was measured by using a 1420 ARVO multi-label counter (produced by Wallac,
20 measurement time: 1 second). The measured values (with no addition of sample or addition of the inhibition sample) are shown in Table 3.

Table 3: Measured value obtained by method utilizing immobilization of chimeric protein (in the presence of botrocetin)

Average value of count in control	37267 counts
Average value of count with addition of AJvW-2 (10 µg/ml)	2339 counts

5 <2> Measurement of inhibition for binding of chimeric protein by inhibition substance

The measurement was performed in the same manner as in Example 8 <1> except that a binding inhibition substance of which inhibition activity was desired to be measured was added.

As the inhibition substance, AJvW-2 mentioned in Example 5 <1>, which is an anti-human von Willebrand factor monoclonal antibody, and the variant type AS1051 similarly mentioned in Example 5 <1>, which is a human glycoprotein Ib binding protein, were used.

The inhibitory activities of AJvW-2 and the variant type AS1051 for the binding of the chimeric protein (i.e., glycoprotein Ib) are shown in Fig. 9.

20 <3> Detection of binding using ristocetin

Von Willebrand factor labeled with europium (Eu) and a chimeric protein immobilized plate that were prepared in the same manner as the above <1> were used. Each well of the chimeric protein immobilized plate was washed 3 times with TBS (150 µl) containing 0.05% Tween-

20. Then, each well of the above plate was added with
25 µl of the assay buffer (Assay Buffer, 1244-106,
produced by Wallac, composition was mentioned in Example
4 <2>) or the recombinant AS1051 (in which Cys81 was
5 replaced with Ala) at a final concentration of 20 µg/ml,
further added with an assay buffer (25 µl) containing
von Willebrand factor (500 ng/ml) and ristocetin sulfate
(produced by Sigma) at one of various concentrations (2,
1, 0.5, 0.25 and 0 mg/ml), and left stand at room
10 temperature for 2 hours. Each well of the plate was
washed 5 times with TBS (150 µl) containing 0.05% Tween-
20, added with 100 µl of a fluorescence enhancement
buffer (Enhancement solution, 1244-104, produced by
Wallac, composition was mentioned in Example 4 <2>), and
15 shaken for 1 minute. Then, the amount of europium (Eu)
was measured by using a 1420 ARVO multi-label counter
(produced by Wallac, measurement time: 1 second). The
concentration of ristocetin, count of bound von
Willebrand factor, and count of von Willebrand factor
20 bound in the presence of the recombinant AS1051 (final
concentration: 20 µg/ml) are shown in Table 4.

Table 4: Binding amount of von Willebrand factor at various ristocetin concentrations (measured values)

Ristocetin concentration	Binding amount (count)	Binding amount in the presence of inhibition substance (count)
2 mg/ml	46213 counts	6884 counts
1 mg/ml	13327 counts	3015 counts
0.5 mg/ml	3665 counts	1852 counts
0.25 mg/ml	3008 counts	3083 counts
0 mg/ml	2818 counts	3246 counts

Example 9: Screening of substance that inhibits binding

5 of glycoprotein Ib and von Willebrand factor using
 method of Example 7

A substance that inhibits the binding of glycoprotein Ib and von Willebrand factor was screened by using the method of Example 7. Specifically, it was
 10 performed in the same manner as in Example 7 <1> except that a sample of which inhibitory activity was desired to be measured was added. Various compounds, culture broth of actinomycetes, filamentous fungi and so forth
 or organic solvent extracts thereof were used as samples.

15 As a result, a substance that markedly inhibited the binding of glycoprotein Ib and von Willebrand factor was found in culture broth of AJ9553 strain of actinomycete collected from soil of Shiki no Mori Koen in Yokohama-shi, Kanagawa-ken, Japan or its organic
 20 solvent (butanol and ethyl acetate) extraction fraction.

Example 10: Production, isolation and structural
analysis of inhibition substance using actinomycete

AJ9553 strain

<1> Method for producing K17427A and K17427B from AJ9553
5 strain

The AJ9553 strain was inoculated to 5 ml of a seed
culture medium (containing 0.1% beef extract (produced
by DIFCO), 1% glucose, 1% starch soluble (produce by
Nakarai Tesque), 0.5% corn steep powder (produced by
10 Wako Pure Chemicals), 1% polypeptone (produced by
Dainippon Pharmaceutical), 0.5% yeast extract (produced
by DIFCO) and 0.2% calcium carbonate, pH 7.2) contained
in a test tube, and cultured at 28°C for 6 days with
shaking at 120 rpm. This culture broth was inoculated
15 at a concentration of 2% to 70 ml of culture medium
(containing 2% glycerol, Pharmamedia (produced by
Traders Protein), 1% corn steep powder (produced by
Nakarai Tesque), 0.4% calcium carbonates, 0.3% sodium
sulfate and 0.003% of zinc sulfate heptahydrate, pH 7.0)
20 contained in a 500-ml volume Erlenmeyer flask, and
further cultured at 28°C for 8 days with shaking at 180
rpm.

From the culture broth (1.6 L) obtained as
described above, cells were collected by centrifugation,
25 and acetone (1 L x 2) was added to the cells to extract
them at room temperature for 1 day. The cell debris was
separated by filtration, and then the acetone was

evaporated under reduced pressure. The obtained residue was suspended in water. This aqueous suspension was adjusted to pH 2.0 with 5% hydrochloric acid, and added with ethyl acetate (400 ml x 2) to extract it. The
5 ethyl acetate layer was concentrated under reduced pressure, and the obtained residue (1.3 g) was dissolved in 50% methanol. This solution was eluted with methanol using a column filled with DIA ION HP-20 (Mitsubishi Chemical). The obtained fraction was purified by HPLC
10 using an ODS column (YMC-Pack AM-322) to obtain K17427A (400 mg) and K17427B (40 mg).

<2> Method for producing K17427C and K17427D from AJ9553 strain

15 The AJ9553 strain was inoculated to 5 ml of a seed culture medium (containing 0.1% beef extract (produced by DIFCO), 1% glucose, 1% starch soluble (produce by Nakarai Tesque), 0.5% corn steep powder (produced by Wako Pure Chemicals), 1% polypeptone (produced by
20 Dainippon Pharmaceutical), 0.5% yeast extract (produced by DIFCO) and 0.2% calcium carbonate, pH 7.2) contained in a test tube, and cultured at 28°C for 6 days with shaking at 120 rpm.

From the culture broth (40 ml) obtained as
25 described above, cells were collected by centrifugation, and acetone (1 L x 2) was added to the cells to extract them at room temperature for 1 day. The cell debris was

separated by filtration, and then the acetone was evaporated under reduced pressure. The obtained aqueous suspension was adjusted to pH 2.0 with 5% hydrochloric acid, and added with ethyl acetate (20 ml x 2) to
 5 extract it. The ethyl acetate layer was concentrated under reduced pressure, and the obtained residue was dissolved in 50% methanol. This solution was eluted with methanol using a column filled with DIA ION HP-20 (Mitsubishi Chemical). The obtained fraction was
 10 fractionated by preparative silica gel TLC (Merck, n-hexane/ethyl acetate/methanol/water = 60:40:5:0.5) to obtain K17427C (3.2 mg) and K17427D (2.2 mg).

Example 11: Identification and physiological test of
 15 actinomycete AJ9553 strain producing low molecular
weight substance K17427A, B, C and D, which inhibit
binding of glycoprotein Ib and von Willebrand factor

The results of taxonomic examination of the AJ9553 strain producing K17427A, B, C and D are shown below.

20

1. Morphological characteristics

After culture on the agar medium defined by ISP (International Streptomyces Project) at 28°C for 14 days, it was found by microscopic observation that substrate
 25 mycelia fairly elongated and branched, and exhibited orange color. The zigzag elongation like *Nocardia* strains was not observed. Aerial mycelia were formed

from substrate mycelia, and spore chains were formed after maturation. Sporangia were not formed. Spores were arthrospores in an egg-like shape or single rod-like shape, and they usually had a size of 0.4 to 1 x 1
5 to 1.5 μm . When matured spores were put into water, the spores had flagella and showed migration property.

2. Growth on various agar media and appearance of cultured actinomycete

10 Growth on various agar media and appearance of the cultured actinomycete (cultured at 28°C for 14 days) are shown in Table 5.

Table 5: Growth on various agar media and appearance of the cultured actinomycete (cultured at 28°C for 14 days)

Medium	Growth	Color of substrate mycelium	Sporangium	Soluble pigment
Yeast-malt agar medium (ISP-2)	Good	Orange	Not formed	Yellow
Oatmeal agar medium (ISP-3)	Good	Dark yellow	Not formed	Yellow
Starch-mineral salt agar medium (ISP-4)	Good	Yellow	Slightly formed	Yellow
Glycerin-asparagine agar medium (ISP-5)	Good	Pale orange	Not formed	Not observed
Tyrosine agar medium (ISP-7)	Good	Reddish brown	Abundantly formed	Dark brown (melanin-like)
Nutrient agar medium	Normal	Reddish orange	Not formed	Yellow
Aqueous agar	Poor	Pale yellow	Abundantly formed	Not observed

3. Growth Temperature

5 Growth states after culture on the oatmeal agar medium for 14 days are represented below.

8°C: No growth	30°C: Good growth
18°C: Slight growth	37°C: Good growth
20°C: Normal growth	42°C: Normal growth
10 28°C: Good growth	45°C: No growth

4. Utilization of carbon source

The strain was cultured at 28°C for 14 days on

Pridham-Gottlieb's agar as a basal medium supplemented with each of the following various saccharides. The growth conditions are shown below. "-" indicates no growth, and "+" indicates normal growth.

5	D-Glucose	+	Raffinose	-
	D-Xylose	+	D-Mannitol	+
	L-Arabinose	+	Inositol	-
	L-Rhamnose	+	Sucrose	+
	D-Fructose	+	D-Galactose	+

10

5. Cell components

There were found meso-diaminopimelate, 3-OH-diaminopimelate, glycine and lysine in the cell wall, and the cell fluid type was considered to be VI type.

- 15 The total cell saccharide components, which constitute a taxonomic characteristic, were arabinose and xylose, and hence the saccharide pattern was D type. The major menaquinone was MK-9 (H4). Further, the acyl type of the cell wall peptidoglycan was glycolyl type.

20

6. Nucleotide sequence analysis of 16S ribosome.RNA

Nucleotide sequence analysis of 16S ribosome RNA of this strain revealed that this strain was most close to *Couchioplanes caeruleus* belonging to the family

25 *Micromonosporacea*.

Based on the above, it was clear that the strain

belonged to the genus *Couchioplanes* among actinomycetes, and thus the AJ9553 strain was decided to be referred to as *Couchioplanes* sp. AJ9553.

This strain was deposited at the National
5 Institute of Bioscience and Human-Technology, Agency of
Industrial Science and Technology, Ministry of
International Trade and Industry (postal code: 305-8566,
1-3, Higashi 1-chome, Tsukuba-shi, Ibaraki-ken, Japan)
on January 6, 1999 under the provisions of the Budapest
10 Treaty, and given an accession number of FERM BP-6612.

In the present invention, derivatives of
Couchioplanes sp. AJ9553 such as variant strains thereof
can also be used for the production of the inhibition
substance so long as they have a property for producing
15 an inhibition substance, even though they have
physiological characteristics different from those of
the strain. A variant strain can be obtained by
mutating *Couchioplanes* sp. AJ9553 by means of a usual
method for mutagenizing a bacterial strain, for example,
20 irradiation treatment such as irradiation with X-rays or
ultraviolet rays, treatment with a mutagenizing agent
such as nitrogen mustard, azaserine, nitrous acid, 2-
aminopurine and N-methyl-N'-nitrosoguanidine (NTG),
contact with phage, transformation, transfection,
25 conjugation and so forth.

Example 12: Inhibitory activity of K17427A, C and D for
binding of glycoprotein Ib and von Willebrand factor

<1> Measurement of inhibitory activity of K17427A, C and
D using method of Example 4 for detecting inhibition for
5 binding of glycoprotein Ib and von Willebrand factor

The inhibitory activity of the isolated K17427A, C
and D for the binding of glycoprotein Ib and von
Willebrand factor was measured in the same manner as
Example 4, except that a 1420 ARVO multi-label counter
10 (produced by Wallac, measurement time: 1 second) was
used for the measurement. The inhibitory activity of
each compound for the binding of glycoprotein Ib and von
Willebrand factor was shown in Fig. 10.

15 <2> Measurement of inhibitory activity of K17427A, C and
D for binding of I¹²⁵-labeled von Willebrand factor and
formalin-fixed platelets

(1) Preparation of fixed platelets

Fixed platelets were prepared as follows. 50 ml
20 of blood collected from healthy volunteers using an
injection needle of 18G was added with 1/10 volume of
3.8% sodium citrate, divided into two 50-ml disposable
tubes (Falcon 2096) in equal volumes, and centrifuged at
900 rpm for 15 minutes at room temperature by using a
25 refrigerated centrifuge (KUBOTA 8800) to collect the
supernatant as platelet rich plasma (PRP). PRP was
added with an equal volume of 2% paraformaldehyde/PBS,

gently stirred and left stand overnight at 4°C. The solution was centrifuged at 3000 rpm for 10 minutes using the same refrigerated centrifuge as above, and the supernatant was removed by decantation. The
5 precipitates were added with about 20 ml of PBS and suspended with gentle pipetting. After the centrifugation at 3000 rpm for 10 minutes and suspension with PBS were further repeated twice, and then a PBS solution of the same volume as the original PRP amount
10 was finally obtained and used as fixed platelet suspension.

(2) Purification of von Willebrand factor from human serum

15 Von Willebrand factor was purified from human serum according to the method to H.R. Gralnick et al. (*J. Clin. Invest.*, 62, 496 (1978)).

(3) Labeling of von Willebrand factor with ^{125}I

20 In a tube in which labeling with ^{125}I was to be performed, Iodogen (produced by Pierce) was immobilized as a solid phase beforehand by adding 1.5 ml of a solution of Iodgen (0.5 mg/ml) in dichloromethane to the tube and removing the solvent under argon flow. High
25 molecular weight von Willebrand factor (0.19 mg/1.5 ml) obtained by gel filtration was introduced into the reaction tube, added with 18.5 Mbq of Na^{125}I , and allowed

to react at room temperature for 2 minutes. The reaction mixture was applied to a PD10 (produced by Pharmacia Biotech) column blocked with BSA and washed beforehand, and eluted with TBS. The eluate was
5 collected as 0.5-ml fractions, and ^{125}I specific activity of each fraction was measured by using a gamma counter, Packard Multi Prias 4. The fractions containing ^{125}I -von Willebrand factor in a large amount were combined, then divided into several tubes and stored at -80°C until use.

10

(4) Measurement of inhibitory activity of K17427A, C and D for binding of ^{125}I -von Willebrand factor to immobilized platelets

A 96-well filter plate, Millipore Multiscreen HV
15 (produced by Millipore, 0.45 μM), on which the assay was to be performed, was preliminarily blocked by adding 1% BSA/TBS (100 μl) to each well of the filter and leaving it stand for several hours. Then, 20 μl of a suspension obtained by diluting the aforementioned immobilized
20 platelet suspension 10-fold with TBS and 5 μl of a test sample were added to each well, and 25 μl (about 800,000 cpm) of ^{125}I -von Willebrand factor solution containing 0.8 $\mu\text{g}/\text{ml}$ of botrocetin or 2.4 mg/ml of ristocetin was further added to each well. The filter plate was left
25 stand for 30 minutes. The solution in the wells was filtered by suction, and each well was washed by adding TBS (100 μl) containing 0.05% Tween-20 and sucking it.

The measurement using the gamma counter was performed as follows. Filter pieces were cut from the 96-well filter plate after the above washing by using a punch (produced by Millipore, Model number: MAPK 896 OB),
5 put into 6-ml volume polystyrene tubes respectively, and measured for radiation dose of ^{125}I by using Packard Multi Prias 4. The inhibitory activities of K17427A, C and D are shown in Fig. 11.

As shown in the aforementioned results of <1> and
10 <2>, the inhibitory activities of K17427A, C and D enabled the detection with higher sensitivity by the method of <1> (the method of Example 4) according to the present invention, compared with the usually and widely used method described in <2>.

15

Example 13: Inhibitory activity of K17427A for
platelet aggregation

50 ml of blood collected from healthy volunteers using an injection needle of 18G was added with 1/10
20 volume of 3.8% sodium citrate, divided into two 50-ml disposable tubes (Falcon 2096) in equal volumes, and centrifuged at 900 rpm for 15 minutes at room temperature by using a refrigerated centrifuge (produced by TOMY) to collect the supernatant as platelet rich
25 plasma (PRP). The lower layer was further centrifuged at 1500 rpm for 10 minutes at room temperature, and the supernatant was collected as platelet poor plasma (PPP).

The platelet aggregation inhibitory activity of a test sample was measured by using PRP prepared as described above and Hematracer 801 (produced by Niko Bioscience) as a measurement apparatus. A special cuvette for the measurement preliminarily containing a test sample (2.5 to 5 μ l) was added with 100 μ l of PRP and mounted on the measurement apparatus. The sample was stirred for 2 minutes (37°C), added with a aggregation substance solution of 10-fold concentration, and measured for change of light transmission. The light transmitting PRP was taken as 0%, and the light transmitting PPP as 100%. The aggregation inhibition ratio obtained by the inhibition substance was numerically represented according to the following equation.

15

Aggregation inhibition ratio =

$$\frac{100 - (\text{Aggregation ratio with addition of inhibition substance} - \text{Aggregation ratio immediately after addition of aggregation substance})}{\text{Control aggregation ratio} - \text{Aggregation ratio immediately after addition of aggregation substance}} \times 100$$

20

As the aggregation inducing substance, ristocetin sulfate (produced by Sigma, final concentration: 1.2 mg/ml), adenosine diphosphate (ADP, produced by MC Medical, final concentration: 10 μ M) and collagen (produced by MC Medical, final concentration: 10 μ g/ml)

25

were used.

The inhibitory activities of K17427A for the aggregation induced by each aggregation inducing substance are shown in Fig. 12. The aggregation inhibition ratios at various concentrations for platelet aggregation caused by each aggregation inducing substance, which were calculated as described above, are shown in Table 4.

Table 4: Aggregation inhibition ratios at various concentrations of K17427A for platelet aggregation caused by each aggregation inducing substance

	Ristocetin aggregation	ADP aggregation	Collagen aggregation
1 mM	100%	24%	1%
0.5 mM	84%	8%	0%
0.25 mM	0%	7%	-7%

Although K17427A completely inhibited the aggregation induced by ristocetin at a concentration of 500 μ M or higher, it did not substantially inhibit the aggregation induced by ADP or collagen even at 1 mM. While the inhibition activities of K17427B, C and D were not measured, it can readily be estimated that they similarly specifically inhibit only the aggregation induced by ristocetin, from the facts that they have highly analogous structures and they inhibit the binding of glycoprotein Ib and von Willebrand factor as shown in Example 12.

Industrial Applicability

According to the present invention, the binding of
5 glycoprotein Ib and von Willebrand factor or inhibition
thereof can be detected in a simple manner. According
to the method of the present invention, there are
provided a simple method for quantification of
glycocalicin with superior quantification ability, and a
10 simple method for measurement of a substance inhibiting
the binding of von Willebrand factor and glycoprotein Ib
with superior operability.

If von Willebrand factor is immobilized in the
presence of a binding inducing substance such as
15 botrocetin, the binding of von Willebrand factor and
glycoprotein Ib can be observed in a simple manner with
good reproducibility, without adding a binding inducing
substance such as botrocetin or ristocetin to a liquid
phase.

20 Further, by utilizing the chimeric protein of the
present invention, it becomes unnecessary to prepare or
obtain monoclonal antibodies for detection or
quantification of a binding inhibition substance such as
glycocalicin.

25 Moreover, the present invention also provides a
method for preparing a chimeric molecule (chimeric
protein) that comprises a partial protein of

PCT/JP99/00089

glycoprotein Ib bound to the Fc region of immunoglobulin molecule by using animal cells.

What is claimed is:

1. A method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of:
 - immobilizing von Willebrand factor in a reaction vessel in the presence of a substance inducing the binding of von Willebrand factor and glycoprotein Ib, and,
 - reacting the immobilized von Willebrand factor with glycoprotein Ib.
2. The method according to Claim 1, wherein the substance that induces the binding of von Willebrand factor and glycoprotein Ib is botrocetin, ristocetin or the both substances.
3. The method according to Claim 1, wherein glyocalicin is measured by adding a sample containing glyocalicin to the reaction vessel during the reaction of von Willebrand factor and glycoprotein Ib, or prior to the reaction, and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib.
4. The method according to Claim 1, wherein a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib is detected by adding a

sample containing a substance to be detected to the
reaction vessel during the reaction of von Willebrand
factor and glycoprotein Ib, or prior to the reaction,
and detecting inhibition of the binding of von
5 Willebrand factor and glycoprotein Ib.

5. A method for detecting binding of von
Willebrand factor and glycoprotein Ib or inhibition of
the binding, comprising the steps of:
10 binding a chimeric protein that consists of an Fc
region of immunoglobulin molecule fused at its amino
terminus to a partial protein comprising a von
Willebrand factor binding site of glycoprotein Ib α chain
at its carboxyl terminus or the chimeric protein labeled
15 with a labeling substance to von Willebrand factor
immobilized in a reaction vessel, and
detecting the Fc region of the immunoglobulin
molecule or the labeling substance.

20 6. The method according to Claim 5, wherein,
when the chimeric protein is allowed to bind to von
Willebrand factor, or prior to the binding, a substance
that induces the binding of von Willebrand factor and
glycoprotein Ib is added to the reaction vessel.

25

7. The method according to Claim 6, wherein the
substance that induces the binding of von Willebrand

factor and glycoprotein Ib is botrocetin, ristocetin or the both substances.

8. The method according to Claim 6, wherein von Willebrand factor is immobilized in the reaction vessel in the presence of a substance that induces the binding of von Willebrand factor and glycoprotein Ib.

9. The method according to Claim 5, wherein glyocalicin is measured by adding a sample containing glyocalicin to the reaction vessel when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, and detecting inhibition of the binding of von Willebrand factor and the chimeric protein.

10. The method according to Claim 5, wherein a substance that inhibits the binding of von Willebrand factor and glycoprotein Ib is detected by adding a sample containing a substance to be detected to the reaction vessel when the chimeric protein is allowed to bind to von Willebrand factor, or prior to the binding, and detecting inhibition of the binding of von Willebrand factor and the chimeric protein.

11. A method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of

the binding, comprising the steps of:

immobilizing a chimeric protein that consists of
an Fc region of immunoglobulin molecule fused at its
amino terminus to a partial protein comprising a von
5 Willebrand factor binding site of glycoprotein Ib α chain
at its carboxyl terminus in a reaction vessel,

binding von Willebrand factor or labeled von
Willebrand factor to the chimeric protein, and

detecting bound von Willebrand factor or the
10 labeling substance.

12. The method according to Claim 11, wherein,
when the chimeric protein is allowed to bind to von
Willebrand factor, or prior to the binding, a substance
15 that induces the binding of von Willebrand factor and
glycoprotein Ib is added to the reaction vessel.

13. The method according to Claim 12, wherein
the substance that induces the binding of von Willebrand
20 factor and glycoprotein Ib is botrocetin, ristocetin or
the both substances.

14. The method according to Claim 12, wherein
glycocalicin is measured by adding a sample containing
25 glycocalicin to the reaction vessel when von Willebrand
factor is allowed to bind to the chimeric protein, or
prior to the binding, and detecting inhibition of the

binding of von Willebrand factor and the chimeric protein.

15. The method according to Claim 12, wherein a
5 substance that inhibits the binding of von Willebrand factor and glycoprotein Ib is detected by adding a sample containing a substance to be detected to the reaction vessel when von Willebrand factor is allowed to bind to the chimeric protein, or prior to the binding,
10 and detecting inhibition of the binding of von Willebrand factor and glycoprotein Ib.

16. A chimeric protein, which consists of an Fc region of immunoglobulin molecule fused at its amino
15 terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.

17. The chimeric protein according to Claim 16,
20 wherein the immunoglobulin molecule is derived from mouse.

18. A kit for measuring glyco-calicin based on inhibition of a reaction of von Willebrand factor and
25 glycoprotein Ib, comprising von Willebrand factor and a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a

partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus.

5 19. A compound which is detected by the method according to any one of Claims 1, 5 and 12, which has an activity for specifically inhibiting platelet aggregation involving glycoprotein Ib and von Willebrand factor in blood plasma and a molecular weight of not
10 more than 2000.

 20. The compound according to Claim 19, which has a structure represented by the following formula:

15

20

25

wherein R¹ and R² independently represent H or Cl, and R³ represents CH₃ or H.

Abstract

A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of botrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.

SEQUENCE LISTING

<110> Ajinomoto Co., Inc.

<120> Substance with Antithrombic Activity and Method for Detecting
Glycocalicin

<130> OP818PCT

<141> 1999-01-13

<150> JP 10-113962

<151> 1998-04-23

<160> 14

<170> PatentIn Ver. 2.0

<210> 1

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

atctgtgagg tctccaaagt ggccagccac ctagaa

36

<210> 2

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

atatctagat gtgcccaggg attgtggtt

29

<210> 3

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 3

ataaagcttc tcgagtcatt taccaggaga gtggga

36

<210> 4

<211> 684

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1).. (684)

<400> 4

gtg ccc agg gat tgt ggt tgt aag cct tgc ata tgt aca gtc cca gaa	48
Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu	
1 5 10 15	
gta tca tet gtc ttc atc ttc ccc cca aag ccc aag gat gtg ctc acc	96
Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr	
20 25 30	
att act ctg act cct aag gtc acg tgt gtt gtg gta gac atc agc aag	144
Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys	
35 40 45	
gat gat ccc gag gtc cag ttc agc tgg ttt gta gat gat gtg gag gtg	192
Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val	
50 55 60	
cac aca gct cag acg caa ccc cgg gag gag cag ttc aac agc act ttc	240
His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe	
65 70 75 80	
cgc tca gtc agt gaa ctt ccc atc atg cac cag gac tgg ctc aat ggc	288
Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly	
85 90 95	
aag gag ttc aaa tgc agg gta aac agt gca gct ttc cct gcc ccc atc	336
Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile	
100 105 110	
gag aaa acc atc tcc aaa acc aaa ggc aga ccg aag gct cca cag gtg	384
Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val	
115 120 125	
tac acc att cca cct ccc aag gag cag atg gcc aag gat aaa gtc agt	432
Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser	

130	135	140	
ctg acc tgc atg ata aca gac ttc ttc cct gaa gac att act gtg gag	480		
Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu			
145	150	155	160
tgg cag tgg aat ggg cag cca gcg gag aac tac aag aac act cag ccc	528		
Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro			
165	170	175	
atc atg gac aca gat ggc tct tac ttc gtc tac agc aag ctc aat gtg	576		
Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val			
180	185	190	
cag aag agc aac tgg gag gca gga aat act ttc acc tgc tct gtg tta	624		
Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu			
195	200	205	
cat gag ggc ctg cac aac cac cat act gag aag agc ctc tcc cac tct	672		
His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser			
210	215	220	
cct ggt aaa tga			684
Pro Gly Lys			
225			

<210> 5

<211> 227

<212> PRT

<213> Mus musculus

<400> 5

Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu	
1 5 10 15	
Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr	
20 25 30	
Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys	
35 40 45	
Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val	
50 55 60	
His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe	
65 70 75 80	
Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly	
85 90 95	
Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile	
100 105 110	
Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val	
115 120 125	
Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser	

```

      130              135              140
Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu
145              150              155              160
Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro
      165              170              175
Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val
      180              185              190
Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu
      195              200              205
His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser
      210              215              220
Pro Gly Lys
225

```

<210> 6

<211> 1689

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: chimera of genes of Mus musculus and Homo sapiens

<220>

<221> CDS

<222> (1)..(1689)

<220>

<221> sig_peptide

<222> (1)..(48)

<220>

<221> mat_peptide

<222> (49)..(1689)

<400> 6

```

atg cct ctc ctc ctc ttg ctg ctc ctg ctg cca agc ccc tta cac ccc   48
Met Pro Leu Leu Leu Leu Leu Leu Leu Pro Ser Pro Leu His Pro
-16 -15              -10              -5
cac ccc atc tgt gag gtc tcc aaa gtg gcc agc cac cta gaa gtg aac   96
His Pro Ile Cys Glu Val Ser Lys Val Ala Ser His Leu Glu Val Asn
      1              5              10              15
tgt gac aag agg aat ctg acg gcg ctg cct cca gac ctg ccg aaa gac   144

```

Cys	Asp	Lys	Arg	Asn	Leu	Thr	Ala	Leu	Pro	Pro	Asp	Leu	Pro	Lys	Asp		
			20					25					30				
aca	acc	atc	ctc	cac	ctg	agt	gag	aac	ctc	ctg	tac	acc	ttc	tcc	ctg	192	
Thr	Thr	Ile	Leu	His	Leu	Ser	Glu	Asn	Leu	Leu	Tyr	Thr	Phe	Ser	Leu		
		35					40					45					
gca	acc	ctg	atg	cct	tac	act	cgc	ctc	act	cag	ctg	aac	cta	gat	agg	240	
Ala	Thr	Leu	Met	Pro	Tyr	Thr	Arg	Leu	Thr	Gln	Leu	Asn	Leu	Asp	Arg		
		50					55					60					
tgc	gag	ctc	acc	aag	ctc	cag	gtc	gat	ggg	acg	ctg	cca	gtg	ctg	ggg	288	
Cys	Glu	Leu	Thr	Lys	Leu	Gln	Val	Asp	Gly	Thr	Leu	Pro	Val	Leu	Gly		
		65				70				75					80		
acc	ctg	gat	cta	tcc	cac	aat	cag	ctg	caa	agc	ctg	ccc	ttg	cta	ggg	336	
Thr	Leu	Asp	Leu	Ser	His	Asn	Gln	Leu	Gln	Ser	Leu	Pro	Leu	Leu	Gly		
				85					90					95			
cag	aca	ctg	cct	gct	ctc	acc	gtc	ctg	gac	gtc	tcc	ttc	aac	cgg	ctg	384	
Gln	Thr	Leu	Pro	Ala	Leu	Thr	Val	Leu	Asp	Val	Ser	Phe	Asn	Arg	Leu		
			100					105					110				
acc	tcg	ctg	cct	ctt	ggg	gcc	ctg	cgt	ggg	ctt	ggc	gaa	ctc	caa	gag	432	
Thr	Ser	Leu	Pro	Leu	Gly	Ala	Leu	Arg	Gly	Leu	Gly	Glu	Leu	Gln	Glu		
		115					120					125					
ctc	tac	ctg	aaa	ggc	aat	gag	ctg	aag	acc	ctg	ccc	cca	ggg	ctc	ctg	480	
Leu	Tyr	Leu	Lys	Gly	Asn	Glu	Leu	Lys	Thr	Leu	Pro	Pro	Gly	Leu	Leu		
		130				135						140					
acg	ccc	aca	ccc	aag	ctg	gag	aag	ctc	agt	ctg	gct	aac	aac	aac	ttg	528	
Thr	Pro	Thr	Pro	Lys	Leu	Glu	Lys	Leu	Ser	Leu	Ala	Asn	Asn	Asn	Leu		
		145				150					155				160		
act	gag	ctc	ccc	gct	ggg	ctc	ctg	aat	ggg	ctg	gag	aat	ctc	gac	acc	576	
Thr	Glu	Leu	Pro	Ala	Gly	Leu	Leu	Asn	Gly	Leu	Glu	Asn	Leu	Asp	Thr		
				165				170				175					
ctt	ctc	ctc	caa	gag	aac	tcg	ctg	tat	aca	ata	cca	aag	ggc	ttt	ttt	624	
Leu	Leu	Leu	Gln	Glu	Asn	Ser	Leu	Tyr	Thr	Ile	Pro	Lys	Gly	Phe	Phe		
			180					185				190					
ggg	tcc	cac	ctc	ctg	cct	ttt	gct	ttt	ctc	cac	ggg	aac	ccc	tgg	tta	672	
Gly	Ser	His	Leu	Leu	Pro	Phe	Ala	Phe	Leu	His	Gly	Asn	Pro	Trp	Leu		
		195					200					205					
tgc	aac	tgt	gag	atc	ctc	tat	ttt	cgt	cgc	tgg	ctg	cag	gac	aat	gct	720	
Cys	Asn	Cys	Glu	Ile	Leu	Tyr	Phe	Arg	Arg	Trp	Leu	Gln	Asp	Asn	Ala		
		210				215					220						
gaa	aat	gtc	tac	gta	tgg	aag	caa	ggg	gtg	gac	gtc	aag	gcc	atg	acc	768	
Glu	Asn	Val	Tyr	Val	Trp	Lys	Gln	Gly	Val	Asp	Val	Lys	Ala	Met	Thr		
		225				230					235				240		
tct	aac	gtg	gcc	agt	gtg	cag	tgt	gac	aat	tca	gac	aag	ttt	ccc	gtc	816	
Ser	Asn	Val	Ala	Ser	Val	Gln	Cys	Asp	Asn	Ser	Asp	Lys	Phe	Pro	Val		

245	250	255	
tac aaa tac cca gga aag ggg tgc ccc acc ctt ggt gat gaa ggt gac			864
Tyr Lys Tyr Pro Gly Lys Gly Cys Pro Thr Leu Gly Asp Glu Gly Asp			
260	265	270	
aca gac cta tat gat tac tac cca gaa gag gac act gag ggc gat aag			912
Thr Asp Leu Tyr Asp Tyr Tyr Pro Glu Glu Asp Thr Glu Gly Asp Lys			
275	280	285	
gtg cgt gcc aca agg act gtg gtc aag ttc ccc acc aaa gcc cat aca			960
Val Arg Ala Thr Arg Thr Val Val Lys Phe Pro Thr Lys Ala His Thr			
290	295	300	
acc ccc tgg ggt cta ttc tac tca tgg tcc act gct tct cta gac gtg			1008
Thr Pro Trp Gly Leu Phe Tyr Ser Trp Ser Thr Ala Ser Leu Asp Val			
305	310	315	320
ccc agg gat tgt ggt tgt aag cct tgc ata tgt aca gtc cca gaa gta			1056
Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val			
325	330	335	
tca tct gtc ttc atc ttc ccc cca aag ccc aag gat gtg ctc acc att			1104
Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile			
340	345	350	
act ctg act cct aag gtc acg tgt gtt gtg gta gac atc agc aag gat			1152
Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp			
355	360	365	
gat ccc gag gtc cag ttc agc tgg ttt gta gat gat gtg gag gtg cac			1200
Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His			
370	375	380	
aca gct cag acg caa ccc cgg gag gag cag ttc aac agc act ttc cgc			1248
Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg			
385	390	395	400
tca gtc agt gaa ctt ccc atc atg cac cag gac tgg ctc aat ggc aag			1296
Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys			
405	410	415	
gag ttc aaa tgc agg gta aac agt gca gct ttc cct gcc ccc atc gag			1344
Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu			
420	425	430	
aaa acc atc tcc aaa acc aaa ggc aga ccg aag gct cca cag gtg tac			1392
Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr			
435	440	445	
acc att cca cct ccc aag gag cag atg gcc aag gat aaa gtc agt ctg			1440
Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu			
450	455	460	
acc tgc atg ata aca gac ttc ttc cct gaa gac att act gtg gag tgg			1488
Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp			
465	470	475	480

```

cag tgg aat ggg cag cca gcg gag aac tac aag aac act cag ccc atc 1536
Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile
      485                      490                      495
atg gac aca gat ggc tct tac ttc gtc tac agc aag ctc aat gtg cag 1584
Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln
      500                      505                      510
aag agc aac tgg gag gca gga aat act ttc acc tgc tct gtg tta cat 1632
Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His
      515                      520                      525
gag ggc ctg cac aac cac cat act gag aag agc ctc tcc cac tct cct 1680
Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro
      530                      535                      540
ggt aaa tga 1689
Gly Lys
545

```

<210> 7

<211> 562

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: chimera of genes of Mus musculus and Homo sapiens

<400> 7

```

Met Pro Leu Leu Leu Leu Leu Leu Leu Pro Ser Pro Leu His Pro
-16 -15                      -10                      -5
His Pro Ile Cys Glu Val Ser Lys Val Ala Ser His Leu Glu Val Asn
  1              5              10              15
Cys Asp Lys Arg Asn Leu Thr Ala Leu Pro Pro Asp Leu Pro Lys Asp
      20              25              30
Thr Thr Ile Leu His Leu Ser Glu Asn Leu Leu Tyr Thr Phe Ser Leu
      35              40              45
Ala Thr Leu Met Pro Tyr Thr Arg Leu Thr Gln Leu Asn Leu Asp Arg
      50              55              60
Cys Glu Leu Thr Lys Leu Gln Val Asp Gly Thr Leu Pro Val Leu Gly
      65              70              75              80
Thr Leu Asp Leu Ser His Asn Gln Leu Gln Ser Leu Pro Leu Leu Gly
      85              90              95
Gln Thr Leu Pro Ala Leu Thr Val Leu Asp Val Ser Phe Asn Arg Leu
      100             105             110
Thr Ser Leu Pro Leu Gly Ala Leu Arg Gly Leu Gly Glu Leu Gln Glu

```

115	120	125
Leu Tyr Leu Lys Gly Asn Glu Leu Lys Thr Leu Pro Pro Gly Leu Leu		
130	135	140
Thr Pro Thr Pro Lys Leu Glu Lys Leu Ser Leu Ala Asn Asn Asn Leu		
145	150	155
Thr Glu Leu Pro Ala Gly Leu Leu Asn Gly Leu Glu Asn Leu Asp Thr		
165	170	175
Leu Leu Leu Gln Glu Asn Ser Leu Tyr Thr Ile Pro Lys Gly Phe Phe		
180	185	190
Gly Ser His Leu Leu Pro Phe Ala Phe Leu His Gly Asn Pro Trp Leu		
195	200	205
Cys Asn Cys Glu Ile Leu Tyr Phe Arg Arg Trp Leu Gln Asp Asn Ala		
210	215	220
Glu Asn Val Tyr Val Trp Lys Gln Gly Val Asp Val Lys Ala Met Thr		
225	230	235
Ser Asn Val Ala Ser Val Gln Cys Asp Asn Ser Asp Lys Phe Pro Val		
245	250	255
Tyr Lys Tyr Pro Gly Lys Gly Cys Pro Thr Leu Gly Asp Glu Gly Asp		
260	265	270
Thr Asp Leu Tyr Asp Tyr Tyr Pro Glu Glu Asp Thr Glu Gly Asp Lys		
275	280	285
Val Arg Ala Thr Arg Thr Val Val Lys Phe Pro Thr Lys Ala His Thr		
290	295	300
Thr Pro Trp Gly Leu Phe Tyr Ser Trp Ser Thr Ala Ser Leu Asp Val		
305	310	315
Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro Glu Val		
325	330	335
Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu Thr Ile		
340	345	350
Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser Lys Asp		
355	360	365
Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu Val His		
370	375	380
Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg		
385	390	395
Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn Gly Lys		
405	410	415
Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro Ile Glu		
420	425	430
Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln Val Tyr		
435	440	445
Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val Ser Leu		
450	455	460

Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val Glu Trp
 465 470 475 480
 Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln Pro Ile
 485 490 495
 Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn Val Gln
 500 505 510
 Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val Leu His
 515 520 525
 Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His Ser Pro
 530 535 540
 Gly Lys
 545

<210> 8

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 8

agctaggatc cgagcccaga gggcccacaa

30

<210> 9

<211> 44

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:primer

<400> 9

cccaagcttc tcgagacata cctttcattt acccgagtc cggga

44

<210> 10

<211> 729

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:chimera of genes of Mus musculus and Homo sapiens

<220>

<221> CDS

<222> (7).. (708)

<400> 10

```

ggatcc gag ccc aga ggg ccc aca atc aag ccc tgt cct cca tgc aaa      48
      Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys
          1              5              10

tgc cca gca cct aac ctc ttg ggt gga cca tcc gtc ttc atc ttc cct      96
Cys Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro
      15              20              25              30

cca aag atc aag gat gta ctc atg atc tcc ctg agc ccc ata gtc aca      144
Pro Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr
          35              40              45

tgt gtg gtg gtg gat gtg agc gag gat gac cca gat gtc cag atc agc      192
Cys Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser
          50              55              60

tgg ttt gtg aac aac gtg gaa gta cac aca gct cag aca caa acc cat      240
Trp Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His
          65              70              75

aga gag gat tac aac agt act ctc cgg gtg gtc agt gcc ctc ccc atc      288
Arg Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile
          80              85              90

cag cac cag gac tgg atg agt ggc aag gag ttc aaa tgc aag gtc aac      336
Gln His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn
          95              100              105              110

aac aaa gac ctg cca gcg ccc atc gag aga acc atc tca aaa ccc aaa      384
Asn Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys
          115              120              125

ggg tca gta aga gct cca cag gta tat gtc ttg cct cca cca gaa gaa      432
Gly Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu
          130              135              140

gag atg act aag aaa cag gtc act ctg acc tgc atg gtc aca gac ttc      480
Glu Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe
          145              150              155

atg cct gaa gac att tac gtg gag tgg acc aac aac ggg aaa aca gag      528
Met Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu
          160              165              170

cta aac tac aag aac act gaa cca gtc ctg gac tct gat ggt tct tac      576
Leu Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr
          175              180              185              190

ttc atg tac agc aag ctg aga gtg gaa aag aag aac tgg gtg gaa aga      624

```

Phe Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg
 195 200 205
 aat agc tac tcc tgt tca gtg gtc cac gag ggt ctg cac aat cac cac 672
 Asn Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His
 210 215 220
 acg act aag agc ttc tcc cgg act ccg ggt aaa tgaaaggat gtctcgagaa 725
 Thr Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
 225 230
 gctt 729

<210> 11

<211> 233

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: chimera of genes of Mus
 musculus and Homo sapiens

<400> 11

Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro
 1 5 10 15
 Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Phe Phe Pro Pro Lys
 20 25 30
 Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val
 35 40 45
 Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe
 50 55 60
 Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu
 65 70 75 80
 Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His
 85 90 95
 Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys
 100 105 110
 Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser
 115 120 125
 Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met
 130 135 140
 Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro
 145 150 155 160
 Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn
 165 170 175

Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met
 180 185 190
 Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser
 195 200 205
 Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr
 210 215 220
 Lys Ser Phe Ser Arg Thr Pro Gly Lys
 225 230

<210> 12

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 12

agctatctag acgagcccag agggcccaca

30

<210> 13

<211> 1707

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: chimera of genes of Mus musculus and Homo sapiens

<220>

<221> CDS

<222> (1)..(1707)

<220>

<221> sig_peptide

<222> (1)..(48)

<220>

<221> mat_peptide

<222> (49)..(1704)

<400> 13

atg cct ctc ctc ctc ttg ctg ctc ctg ctg cca agc ccc tta cac ccc 48

Met	Pro	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Leu	Pro	Ser	Pro	Leu	His	Pro		
-16	-15					-10				-5							
cac	ccc	atc	tgt	gag	gtc	tcc	aaa	gtg	gcc	agc	cac	cta	gaa	gtg	aac	96	
His	Pro	Ile	Cys	Glu	Val	Ser	Lys	Val	Ala	Ser	His	Leu	Glu	Val	Asn		
1			5					10					15				
tgt	gac	aag	agg	aat	ctg	aca	gcg	ctg	cct	cca	gac	ctg	ccg	aaa	gac	144	
Cys	Asp	Lys	Arg	Asn	Leu	Thr	Ala	Leu	Pro	Pro	Asp	Leu	Pro	Lys	Asp		
		20					25					30					
aca	acc	atc	ctc	cac	ctg	agt	gag	aac	ctc	ctg	tac	acc	ttc	tcc	ctg	192	
Thr	Thr	Ile	Leu	His	Leu	Ser	Glu	Asn	Leu	Leu	Tyr	Thr	Phe	Ser	Leu		
		35					40				45						
gca	acc	ctg	atg	cct	tac	act	cgc	ctc	act	cag	ctg	aac	cta	gat	agg	240	
Ala	Thr	Leu	Met	Pro	Tyr	Thr	Arg	Leu	Thr	Gln	Leu	Asn	Leu	Asp	Arg		
	50						55			60							
tgc	gag	ctc	acc	aag	ctc	cag	gtc	gat	ggg	acg	ctg	cca	gtg	ctg	ggg	288	
Cys	Glu	Leu	Thr	Lys	Leu	Gln	Val	Asp	Gly	Thr	Leu	Pro	Val	Leu	Gly		
65					70				75					80			
acc	ctg	gat	cta	tcc	cac	aat	cag	ctg	caa	agc	ctg	ccc	ttg	cta	ggg	336	
Thr	Leu	Asp	Leu	Ser	His	Asn	Gln	Leu	Gln	Ser	Leu	Pro	Leu	Leu	Gly		
			85					90					95				
cag	aca	ctg	cct	gct	ctc	acc	gtc	ctg	gac	gtc	tcc	ttc	aac	cgg	ctg	384	
Gln	Thr	Leu	Pro	Ala	Leu	Thr	Val	Leu	Asp	Val	Ser	Phe	Asn	Arg	Leu		
		100					105					110					
acc	tgc	ctg	cct	ctt	ggt	gcc	ctg	cgt	ggt	ctt	ggc	gaa	ctc	caa	gag	432	
Thr	Ser	Leu	Pro	Leu	Gly	Ala	Leu	Arg	Gly	Leu	Gly	Glu	Leu	Gln	Glu		
		115					120				125						
ctc	tac	ctg	aaa	ggc	aat	gag	ctg	aag	acc	ctg	ccc	cca	ggg	ctc	ctg	480	
Leu	Tyr	Leu	Lys	Gly	Asn	Glu	Leu	Lys	Thr	Leu	Pro	Pro	Gly	Leu	Leu		
	130				135				140								
acg	ccc	aca	ccc	aag	ctg	gag	aag	ctc	agt	ctg	gct	aac	aac	aac	ttg	528	
Thr	Pro	Thr	Pro	Lys	Leu	Glu	Lys	Leu	Ser	Leu	Ala	Asn	Asn	Asn	Leu		
145					150				155					160			
act	gag	ctc	ccc	gct	ggg	ctc	ctg	aat	ggg	ctg	gag	aat	ctc	gac	acc	576	
Thr	Glu	Leu	Pro	Ala	Gly	Leu	Leu	Asn	Gly	Leu	Glu	Asn	Leu	Asp	Thr		
			165				170				175						
ctt	ctc	ctc	caa	gag	aac	tgc	ctg	tat	aca	ata	cca	aag	ggc	ttt	ttt	624	
Leu	Leu	Leu	Gln	Glu	Asn	Ser	Leu	Tyr	Thr	Ile	Pro	Lys	Gly	Phe	Phe		
		180					185				190						
ggg	tcc	cac	ctc	ctg	cct	ttt	gct	ttt	ctc	cac	ggg	aac	ccc	tgg	tta	672	
Gly	Ser	His	Leu	Leu	Pro	Phe	Ala	Phe	Leu	His	Gly	Asn	Pro	Trp	Leu		
		195				200					205						
tgc	aac	tgt	gag	atc	ctc	tat	ttt	cgt	cgc	tgg	ctg	cag	gac	aat	gct	720	
Cys	Asn	Cys	Glu	Ile	Leu	Tyr	Phe	Arg	Arg	Trp	Leu	Gln	Asp	Asn	Ala		

210	215	220	
gaa aat gtc tac gta tgg aag caa ggt gtg gac gtc aag gcc atg acc			768
Glu Asn Val Tyr Val Trp Lys Gln Gly Val Asp Val Lys Ala Met Thr			
225	230	235	240
tct aac gtg gcc agt gtg cag tgt gac aat tca gac aag ttt ccc gtc			816
Ser Asn Val Ala Ser Val Gln Cys Asp Asn Ser Asp Lys Phe Pro Val			
245	250	255	
tac aaa tac cca gga aag ggg tgc ccc acc ctt ggt gat gaa ggt gac			864
Tyr Lys Tyr Pro Gly Lys Gly Cys Pro Thr Leu Gly Asp Glu Gly Asp			
260	265	270	
aca gac cta tat gat tac tac cca gaa gag gac act gag ggc gat aag			912
Thr Asp Leu Tyr Asp Tyr Tyr Pro Glu Glu Asp Thr Glu Gly Asp Lys			
275	280	285	
gtg cgt gcc aca agg act gtg gtc aag ttc ccc acc aaa gcc cat aca			960
Val Arg Ala Thr Arg Thr Val Val Lys Phe Pro Thr Lys Ala His Thr			
290	295	300	
acc ccc tgg ggt cta ttc tac tca tgg tcc act gct tct cta gac gag			1008
Thr Pro Trp Gly Leu Phe Tyr Ser Trp Ser Thr Ala Ser Leu Asp Glu			
305	310	315	320
ccc aga ggg ccc aca atc aag ccc tgt cct cca tgc aaa tgc cca gca			1056
Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys Pro Ala			
325	330	335	
cct aac ctc ttg ggt gga cca tcc gtc ttc atc ttc cct cca aag atc			1104
Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys Ile			
340	345	350	
aag gat gta ctc atg atc tcc ctg agc ccc ata gtc aca tgt gtg gtg			1152
Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys Val Val			
355	360	365	
gtg gat gtg agc gag gat gac cca gat gtc cag atc agc tgg ttt gtg			1200
Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp Phe Val			
370	375	380	
aac aac gtg gaa gta cac aca gct cag aca caa acc cat aga gag gat			1248
Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg Glu Asp			
385	390	395	400
tac aac agt act ctc cgg gtg gtc agt gcc ctc ccc atc cag cac cag			1296
Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln His Gln			
405	410	415	
gac tgg atg agt ggc aag gag ttc aaa tgc aag gtc aac aac aaa gac			1344
Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp			
420	425	430	
ctg cca gcg ccc atc gag aga acc atc tca aaa ccc aaa ggg tca gta			1392
Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val			
435	440	445	

```

aga gct cca cag gta tat gtc ttg cct cca cca gaa gaa gag atg act 1440
Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr
450 455 460
aag aaa cag gtc act ctg acc tgc atg gtc aca gac ttc atg cct gaa 1488
Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu
465 470 475 480
gac att tac gtg gag tgg acc aac aac ggg aaa aca gag cta aac tac 1536
Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr
485 490 495
aag aac act gaa cca gtc ctg gac tct gat ggt tct tac ttc atg tac 1584
Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr
500 505 510
agc aag ctg aga gtg gaa aag aag aac tgg gtg gaa aga aat agc tac 1632
Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr
515 520 525
tcc tgt tca gtg gtc cac gag ggt ctg cac aat cac cac acg act aag 1680
Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys
530 535 540
agc ttc tcc cgg act ccg ggt aaa tga 1707
Ser Phe Ser Arg Thr Pro Gly Lys
545 550

```

<210> 14

<211> 568

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: chimera of genes of *Mus musculus* and *Homo sapiens*

<400> 14

```

Met Pro Leu Leu Leu Leu Leu Leu Leu Pro Ser Pro Leu His Pro
-16 -15 -10 -5
His Pro Ile Cys Glu Val Ser Lys Val Ala Ser His Leu Glu Val Asn
1 5 10 15
Cys Asp Lys Arg Asn Leu Thr Ala Leu Pro Pro Asp Leu Pro Lys Asp
20 25 30
Thr Thr Ile Leu His Leu Ser Glu Asn Leu Leu Tyr Thr Phe Ser Leu
35 40 45
Ala Thr Leu Met Pro Tyr Thr Arg Leu Thr Gln Leu Asn Leu Asp Arg
50 55 60
Cys Glu Leu Thr Lys Leu Gln Val Asp Gly Thr Leu Pro Val Leu Gly

```

65		70		75		80									
Thr	Leu	Asp	Leu	Ser	His	Asn	Gln	Leu	Gln	Ser	Leu	Pro	Leu	Leu	Gly
		85						90						95	
Gln	Thr	Leu	Pro	Ala	Leu	Thr	Val	Leu	Asp	Val	Ser	Phe	Asn	Arg	Leu
		100						105						110	
Thr	Ser	Leu	Pro	Leu	Gly	Ala	Leu	Arg	Gly	Leu	Gly	Glu	Leu	Gln	Glu
		115						120						125	
Leu	Tyr	Leu	Lys	Gly	Asn	Glu	Leu	Lys	Thr	Leu	Pro	Pro	Gly	Leu	Leu
		130						135						140	
Thr	Pro	Thr	Pro	Lys	Leu	Glu	Lys	Leu	Ser	Leu	Ala	Asn	Asn	Asn	Leu
		145						150						155	
Thr	Glu	Leu	Pro	Ala	Gly	Leu	Leu	Asn	Gly	Leu	Glu	Asn	Leu	Asp	Thr
				165						170					175
Leu	Leu	Leu	Gln	Glu	Asn	Ser	Leu	Tyr	Thr	Ile	Pro	Lys	Gly	Phe	Phe
			180							185				190	
Gly	Ser	His	Leu	Leu	Pro	Phe	Ala	Phe	Leu	His	Gly	Asn	Pro	Trp	Leu
		195						200						205	
Cys	Asn	Cys	Glu	Ile	Leu	Tyr	Phe	Arg	Arg	Trp	Leu	Gln	Asp	Asn	Ala
		210						215						220	
Glu	Asn	Val	Tyr	Val	Trp	Lys	Gln	Gly	Val	Asp	Val	Lys	Ala	Met	Thr
		225						230						235	
Ser	Asn	Val	Ala	Ser	Val	Gln	Cys	Asp	Asn	Ser	Asp	Lys	Phe	Pro	Val
				245						250				255	
Tyr	Lys	Tyr	Pro	Gly	Lys	Gly	Cys	Pro	Thr	Leu	Gly	Asp	Glu	Gly	Asp
		260						265						270	
Thr	Asp	Leu	Tyr	Asp	Tyr	Tyr	Pro	Glu	Glu	Asp	Thr	Glu	Gly	Asp	Lys
		275						280						285	
Val	Arg	Ala	Thr	Arg	Thr	Val	Val	Lys	Phe	Pro	Thr	Lys	Ala	His	Thr
		290						295						300	
Thr	Pro	Trp	Gly	Leu	Phe	Tyr	Ser	Trp	Ser	Thr	Ala	Ser	Leu	Asp	Glu
		305						310						315	
Pro	Arg	Gly	Pro	Thr	Ile	Lys	Pro	Cys	Pro	Pro	Cys	Lys	Cys	Pro	Ala
				325						330				335	
Pro	Asn	Leu	Leu	Gly	Gly	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Lys	Ile
		340						345						350	
Lys	Asp	Val	Leu	Met	Ile	Ser	Leu	Ser	Pro	Ile	Val	Thr	Cys	Val	Val
		355						360						365	
Val	Asp	Val	Ser	Glu	Asp	Asp	Pro	Asp	Val	Gln	Ile	Ser	Trp	Phe	Val
		370						375						380	
Asn	Asn	Val	Glu	Val	His	Thr	Ala	Gln	Thr	Gln	Thr	His	Arg	Glu	Asp
		385						390						395	
Tyr	Asn	Ser	Thr	Leu	Arg	Val	Val	Ser	Ala	Leu	Pro	Ile	Gln	His	Gln
				405						410				415	

Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn Lys Asp
 420 425 430
 Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly Ser Val
 435 440 445
 Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu Met Thr
 450 455 460
 Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met Pro Glu
 465 470 475 480
 Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu Asn Tyr
 485 490 495
 Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe Met Tyr
 500 505 510
 Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn Ser Tyr
 515 520 525
 Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr Thr Lys
 530 535 540
 Ser Phe Ser Arg Thr Pro Gly Lys
 545 550